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ABSTRACT 
Genome editing techniques and platforms for nucleic acid targeting have been revolutionized by the 
discovery and technological adaptation of bacterial immune systems called CRISPR systems.  These 
immune systems can specifically recognize, bind to, and cleave substrate nucleic acids to prevent phage 
infection for the bacterial strains which contain them.  In genetic manipulation technologies, CRISPR 
systems allow for a high degree of targeting versatility along with simplified experimental design 
compared to other platforms.  While Cas9 technologies continue to prove successful, other CRISPR 
systems exist which deserve investigation for their unique biochemical properties. 
In this thesis, I first provide background on the mechanisms of CRISPR biochemistry.  I focus primarily on 
the Type I-E CRISPR systems of E. coli and T. fusca (Cascade and Cas3) and make analogies to the well-
characterized Type II-A system of S. pyogenes (Cas9).  I provide some background on the discovery of 
CRISPR systems and touch on the organization and diversity of these immune systems in nature.  I then 
also discuss some current trends in CRISPR technology, and since most of these technologies utilize the 
Cas9 platform, I discuss Cas9 in more detail.  
Then I explore the mechanism of interaction between Cas3 and Cascade by mutational interface 
perturbation.  The linker-helix region of Cas3 has been established to be important for the interaction 
 
 
between Cascade and Cas3.  However, the precise mechanism was difficult to determine without a 
detailed structure of Cascade interacting with Cas3.  While there now exists a Cascade-Cas3 high-
resolution Cryo-EM structure, my mutational analysis confirms that the interface at the linker helix is 
extensive and redundant.  However, my analysis also suggests a more nuanced and not completely 
understood mechanism, since there were several mutations which caused observed binding defects 
which did not participate in the Cascade-Cas3 interface in the Cryo-EM structure. 
Next I describe a genome editing technology based on the Type I-E CRISPR system of T. fusca which we 
applied in a human embryonic stem cell (hESC) line.  When applied to hESCs, the Type I-E system 
introduces a spectrum of deletions that are caused by Cas3 and Cascade.  These deletions have non-
determinate start and stop sites, ranging from several hundred bases to many kilobases deleted.  These 
deletions did not start at the targeting site, implying that some distance of Cas3 translocation is required 
before double-strand breaks are induced. 
Finally, I describe efforts to elucidate the mechanism of Cas3-induced double-strand breaks.  The 
observation that DSBs form distal to the target site in Cascade/Cas3-mediated genome editing implies a 
new mechanism of Cas3 activity.  I present speculation and preliminary data which suggests that Cas3 
dimerization is a plausible hypothesis to explain this behavior and I provide a road-map for investigation.
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CHAPTER 1 – INTRODUCTION 
1.1 Introduction and general principles of CRISPR 
The struggle between host genomes and invading genomes has been a defining drama of evolutionary 
history.  At its core, the drive for a genome to defend itself from invaders is central to life itself on the 
most basic level.  The need to evade, neutralize, or incapacitate invaders has caused a vast array of 
defenses to spring up in all branches of life from simple bacterial restriction enzymes to the complex 
immune responses in mammals.  As the effectiveness of these systems improve, viruses and other 
invaders acquire their own mechanisms of escape and resistance to systems of immunity.  Thus, there is 
a strong advantage to any immune system which can adapt to neutralize a diversity of invaders while 
also limiting the possibility of escape or resistance in viruses. 
Adaptive immune systems are those which can sense an invader, affect immunity to the invader, and 
afterwards retain a memory of the infection – making a future infection less costly or impossible.  These 
principles are applied in the adaptive immune response of mammals where genetic memory of antibody 
structural recognition of an invader is retained in Memory B cells and can be called up to neutralize a 
future infection (1).  Likewise, bacteria have an adaptive immune response with strong analogies to the 
mammalian case (2).  In this case, instead of protein-protein interactions mediating the recognition of 
viral or bacterial surface proteins, in bacteria, RNA-guided recognition directly recognizes the genomes 
of invading phages (3-6). 
These bacterial adaptive immune systems are known as CRISPR (Clustered Regularly Interspaced Short 
Palindromic Repeat) systems, named so after their hallmark genetic element, the CRISPR array (7).  
These arrays are a genetic memory of previous phage infections and are passed down from mother cell 
to daughter cell within a population (8).  These arrays are themselves comprised of the “Repeat” 
element – a sequence that, when transcribed into RNA often forms a structured region – and “Spacers” 
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(Figure 1.1a).  Spacers are sequences that are derived from invader genomes and represent the library 
of nucleic acid sequences targeted by a given CRISPR array (9).  CRISPR arrays have no defined maximum 
size, though there has been analysis that suggest there is an optimal CRISPR array size which is 
dependent on the environmental diversity of phage (10, 11).  In contrast, the minimally defined CRISPR 
array that can affect immunity is a single spacer flanked by two repeats (12). 
CRISPR systems mediate their function by processing the CRISPR array tandem transcripts into individual 
units, called CRISPR RNA (crRNA) (13).  This processing is performed in various ways and by various 
RNAses, and likewise the repeat-derived region of the crRNA can vary from a structured element, as in 
most Class I Systems, to a simple sequence that forms a duplex with a Trans-Activating CrRNA 
(tracrRNA), as in some Class II (14, 15) (Figure 1.1b).  The tracrRNA for some Class II systems serves as a 
means of validating that minimally-structured Class II crRNAs are properly loaded by verifying through 
base-pairing that the RNAs originated from the crArray and not some other improper origin. 
CRISPR diversity is vast and the mechanisms employed are as well (16-19).  CRISPR systems have been 
observed to have anywhere from one single effector protein to large multi-sub-unit complexes.  These 
proteins associate with the crRNA and use the crRNA as guides to detect foreign nucleic acids.  The 
proteins associated with CRISPR Arrays are called Cas (CRISPR-Associated) proteins (20).  In all CRISPR 
systems, acquisition machinery is lumped together with the recognition and nuclease machinery in a 
genetic element called the Cas Operon (17, 20) (Figure 1.1c).  Acquisition proteins are responsible for 
acquiring new spacers and specifically integrating them into the host genome at the CRISPR array (21-
23). 
The use of bacterial immune systems for technological applications has a robust history and has been 
integral to the advancement of biological science, starting with the first applications of restriction 
enzymes to map genomes in 1971 and progressing through the currently developing CRISPR/Cas 
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revolution (24).  Surely, the full potential of exogenously-applied bacterial immunity mechanisms has 
not yet been depleted.  
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a) 
 
b) 
 
c) 
 
Figure 1.1: Structure of CRISPR Genetic Elements. a) The generalized composition which is shared by all 
crArray loci.  The locus is comprised of a unique Leader sequence (blue) which is crucial for integration of new 
spacers into the array.  The repeat sequence (orange) immediately follows the Leader and is also between each 
invader-derived spacer sequence (various colors).  b) The Repeat region of the crArray in the Type I system, when 
transcribed into RNA, folds into a structured region.  This stem loop serves as a recognition element for both the 
processing of the CrArray transcript into individual crRNA and as the first point of contact between the protein 
sub-units of the Cascade complex and the crRNA. c) The construction of the genetic elements of the CRISPR locus.  
The operon can be divided into groups of genes involved in either CRISPR interference or CRISPR acquisition.  In 
the Class I CRISPR system, the interference proteins form a multi-subunit complex.  In Class II, the interference 
modules are comprised of a single protein.  In both classes, the Acquisition modules at the least contain the 
signature Cas1/Cas2 proteins, but may also contain others.  
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1.2 CRISPR Classification 
One of the minor but seemingly constant hazards inherent to working in a new field as it matures is the 
evolving and conflicting terminology, classifications, and nomenclature.  In this, CRISPR systems are no 
exception and, as an aid to the reader in following past literature, a brief review of the history of CRISPR 
and a summary of classification conventions is helpful.  I will not endeavor to make this the most 
complete or nuanced version of such a review as others have recorded the history of CRISPR first-hand 
(25-28), and others have more exhaustively described the organization of CRISPR systems into their 
various Classes, Types, and Sub-Types (16, 17). 
In short, and for quick reference, a table of the CRISPR systems most likely to be familiar to the reader is 
provided (Table 1).  This does not represent the sum total of all CRISPR systems nor all Cas proteins, as 
new CRISPR systems are still currently being discovered.  In some earlier literature, the seemingly 
deprecated term RAMP (Repeat Associated Mysterious Protein) was used to describe some Cas genes 
(29).   
CRISPR systems are first divided into “Class”, of which there are only two recognized categories: Class 1 
and Class 2.  The Class 1 systems are those which have multi-sub-unit effector complexes and Class 2 
systems have single-component effector complexes.  Both require crRNA and rely on the same general 
principles of target recognition.  The next-finer division occurs at the “Type”.  There are 5 categorized 
types which are determined by the Class as well as the substrate (DNA/RNA/Both) and characteristic 
proteins of the CRISPR system (16, 17, 19, 30).   
  
6 
 
Table 1.1:  CRISPR/Cas nomenclature conventions.  Reference for the organization of CRISPR systems 
and for deprecated/less used names that appear in the literature. 
Class CRISPR Type Target Cas Protein Name Other Names 
1 I DNA Cse1 CasA, Cas8 
   Cse2 CasB 
   Cas6e CasE, Cas6e 
   Cas7 CasC, Cse4 
   Cas5e CasD 
   Cas31  
Shared Acquisition - - Cas1  
Shared Acquisition - - Cas2  
2 II DNA Cas9  
1 III RNA2 Cas10  
2 V  Cas12a Cpf1 
 VI  Cas13b C2C2 
 
  
                                                          
1 Cas3 is, in some systems, split into Cas3’ and Cas3’’, splitting the protein into its helicase and nuclease 
domains 
2 Type III systems are also capable of cleaving either DNA, RNA, or both. 
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In this thesis, I will endeavor to maintain a continuous and consistent use of the naming conventions, 
with the primary convention of the Type I-E system being Cse1, Cse2, Cas7, Cas5e, and Cas6e.  I will use 
a combination of T. fusca Cascade and E. coli Cascade as the representative systems of the Class I Type I-
E system as they are the best characterized.  I will use S. pyogenes Cas9 as the representative of a 
generic Class II Type II system for the same reason.  Generally speaking, the Class 2 Type II system is the 
best characterized.  This can be mostly explained by the fact that Cas9 genome editing technologies 
have necessitated and propelled advancements in the mechanistic understanding of Cas9.  Also, since 
Class 2 Type II systems have a single-component effector complex, it is at first approximation easier to 
work with. 
The first mention in the literature of what would later be called the CRISPR locus was in 1987, described 
as “An unusual structure… found in the 3’-end flanking region of iap… Five highly homologous sequences 
of 29 Nucleotides were arranged as direct repeats with 32 nucleotides as spacing.” (31).  At the early 
stages of CRISPR research, the first observation made which indicated that the CRISPR system might be 
some form of an immune system was the identification of the spacer sequences as being viral genome-
derived (8, 32, 33).  The CRISPR locus had already been identified as a repetitive region of DNA that was 
likely to be structured.  Strains of bacteria which contained CRISPR systems were resistant to infection 
by phages or plasmids when the CRISPR region contained spacers originating from the invader, all but 
confirming the role of the CRISPR locus as an immune system (8).  Further genetic evaluation showed 
that the associated Cas genes were necessary for the immune system to function (34).  The 
determination that the Cas genes were essentially RNA-programmable nucleases led to the application 
of Cas9 for gene editing by both the Doudna and Zhang labs (35, 36).  The resulting patent dispute is well 
documented in the literature as well as in popular science reporting (37-41).  CRISPR has even 
penetrated popular culture with varying degrees of accuracy in the representation of CRISPR-based 
technologies – from CRISPR’s dystopian influence depicted in speculative fiction novels such as Change 
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Agent by Daniel Suarez, or as the unifying theme of a crime-drama executive produced by Jennifer 
Lopez, to using CRISPR to create giant city-destroying monsters in the 2018 major motion picture 
Rampage starring Dwayne “The Rock” Johnson (42-44). 
1.3 CRISPR Mechanisms 
The absolutely conserved mechanism characteristic of CRISPR systems is RNA-mediated target 
recognition.  Without RNA guides, CRISPR systems cease to function since these systems rely on RNA to 
provide specificity, flexibility, and affinity for various target invader nucleic acids.  These mechanisms 
can provide interference against invaders possessing either an RNA or DNA genome.  Another key 
feature that is strongly conserved is the Protospacer Adjacent Motif (PAM).  This small sequence 
adjacent to the target site is required for target recognition in DNA-targeting CRISPR systems (45, 46). 
The central mechanism of target recognition is direct base-pairing between the guide sequence and the 
target (7).  This process is accomplished by progressive unwinding of the substrate DNA and substitution 
of base-pairing with the RNA guide – this is thermodynamically favorable as RNA-DNA heteroduplex is 
stronger than DNA-DNA (47, 48).  Since the RNA guide itself is also strongly held by the Cas machinery, 
generally through non-specific electrostatic interactions, mostly to the phosphate backbone, the base 
pairing between the guide RNA and the substrate results in a strong association between the complex 
and the substrate nucleic acid (49, 50).  In this, too, variations exist in CRISPR systems in terms of the 
length of the guide, degree of base-pairing, and the base-pair fidelity necessary to engage a full R-loop 
(51-54).  For instance, the spCas9 guide is 22 nucleotides long and base pairing is uninterrupted 
throughout the length (49).  In contrast, the Type I systems have variable target lengths.  The tfuCascade 
and ecoCascade guides are 32 nucleotides long, but every 6th nucleotide is flipped away from the target 
sequence (50, 55-58).  This results in a region of specificity that is 27 bases long.  The Type I-C CRISPR 
system of Bacillus halodurans has a variable spacer length, ranging from 32-36 nt (53, 59).  It appears to 
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be a general principle of CRISPR target recognition that base-pair mismatches between the target and 
crRNA on the PAM-distal side is less detrimental than those at the PAM-proximal side (60, 61).  This is 
because R-loop formation, and by proxy target recognition, occurs directionally, starting at PAM 
recognition, formation of a short region of critical base-pairs between the crRNA and the target called 
the seed-bubble, and propagating down the length of the recognized region (62).  Mismatches in the 
seed bubble region carry a heavy penalty for target recognition and mismatches lead to an increased 
chance of rejection of the substrate (58, 60, 62, 63). 
Throughout this work and in much of the literature, targeted DNA sequences are defined in terms of the 
Target Strand and Non-Target Strand (Figure 1.2a).  The Target Strand is that which is directly base-
paired to the crRNA.  The Non-Target Strand is that which has been left as a single-stranded region.  The 
Target Strand/Non-Target Strand convention has no bearing on which strand is modified by the 
CRISPR/cas system or related technology, and is a common source of confusion when discussions of 
CRISPR mechanisms are conducted with experts from outside the field.  PAM Sequences can be located 
on either side of a targeted site depending on the CRISPR system, and are defined by the sequence on 
the non-target strand (49, 55, 64, 65). 
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a) 
  
b) 
 
Figure 1.2: Cascade target recognition and structural schematic.  a)  Schematic of target recognition in 
the Type I system.  The substrate DNA is defined in terms of the Target (the strand which participates in base-
pairing to the crRNA) and Non-target strands (the strand which is looped-out).  The PAM sequence is defined 
on the Non-Target strand.  In the Type I-E system, the crRNA base-pairing is discontinuous with every 6th 
nucleotide flipped away from the substrate. b)  Schematic representation of the Type I-E Cascade complex.  
The type I-E Cascade complex in molar equivalents is comprised of (Cse1)1, (Cse2)2, (Cas7)6, (Cas5e)1, 
(Cas6e)1.  The Cas6e sub-unit which recognizes the stem-loop of the crRNA cleaves the crArray transcript into 
individual sub-units and remains associated.  The rest of the Cascade complex is then assembled along the 
Cas7 backbone with an underbelly of Cse2.  The complex is then capped by Cas5e and the last sub-unit to 
associate is Cse1.  
11 
 
PAM sequence requirements vary in terms of their placement relative to the target sequence, in terms 
of their sequence content, and in terms of their length.  The well-characterized S. pyogenes Cas9 
possesses a three nucleotide PAM sequence on the 3’ end of the targeted sequence on the Non-Target 
Strand (66).  Type I systems have their PAM sequences on the 5’ end of the targeted sequence on the 
Non-Target strand (50, 55, 67).  PAM Specificity and sequence content vary from system to system.  For 
instance, the spCas9 canonical PAM is the NGG PAM (66, 68).  The tfuCascade canonical PAM is AAG (54, 
69).  The mechanisms of PAM recognition can also diverge between different systems.  SpCas9’s PAM 
recognition is mediated through contacts in the major groove between the PAM nucleotides and a 
conserved set of Arginines in the C-terminal domain of Cas9 (70).  By contrast, ecoCascade, and most 
likely all other Type I-E systems at least, recognizes its PAM through contacts in the minor groove 
mediated by contacts to a glycine-rich loop present on Cse1 (55).  In general, failure to recognize a PAM 
sequence results in failure to recognize a target (48, 71). 
How can the PAM sequence be rationalized as such a strict target recognition requirement?  After all, 
target specificity is ensured by the crRNA.  PAM recognition primarily serves as a protection against self-
targeting.  Any crRNA sequence that encodes a guide against a target is a sequence that also exists in the 
host genome at the CRISPR array.  If no PAM sequence were required, all surveillance complexes would 
target the host genome at this locus.  In fact, in CRISPR systems that have a PAM requirement, the PAMs 
with the lowest degree of target recognition are also those sequences which are present in the repeat 
region of the CRISPR array (72).  In other words, the “worst” PAM for interference is that which is 
contained at the CRISPR locus.  An additional supporting argument could be made that the presence of a 
PAM sequence also speeds target recognition, since the recognition mechanisms for PAM sequences do 
not require target unwinding and PAM sequences are short.  This could prevent surveillance complexes 
from spending too much time trying to recognize improper target sequences. 
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1.4 Type I-E CRISPR Structural Overview 
Since this thesis is primarily concerned with the Type I-E CRISPR system, it will be discussed the most in-
depth structurally.  The first Type I-associated structure solved with functional information was Cas6 in 
Pyrococcus furiosus (73).  In Pyrococcus furiosus, one gene copy of Cas6 is used to process crRNAs from 
the Type I-A, Type I-G, and Type III-B systems (74, 75).  This serves as a useful example demonstrating 
that host genomes can contain multiple CRISPR systems and that some components, such as the 
processing or adaptation machinery, might be shared between them.  Cas6 is responsible for recognizing 
the nascent crRNA and cleaving the long transcript into individual crRNA units by recognizing and 
cleaving the repeat elements specifically (76).  In Type I-E systems (in which Cas6-like proteins are called 
Cas6e), once crRNA processing is complete the mature crRNA remains bound to Cas6e and nucleates the 
formation of the Cascade complex (CRISPR-Associated Complex for Anti-viral Defense) (77). 
The first structure of a full Cascade complex was the E. coli Cascade complex (51).  It showed the overall 
architecture of the complex with one copy of Cse1, two copies of Cse2, six copies of Cas7, one copy each 
of Cas5e and Cas6e (Figure 1.2b).  The Cas5e and Cse1 are at one end and Cas6e is at the other.  
Between them, a twisting backbone of Cas7 and an underbelly of Cse2 subunits coat the crRNA along 
the region that contains the targeting information.  Following this, a structure of the E. coli Cascade was 
solved that showed Cascade bound to a single-stranded target, revealing that the substrate and crRNA 
have every sixth nucleotide flipped away from one another, not participating in base-pair mediated 
recognition (50).  This base flipping is a structural requirement, as the DNA-RNA heteroduplex is 
significantly distorted from ideal B-form DNA. 
Hochstrasser et al. 2014 solved the first Cascade-Cas3 structure; the Cryo-EM map showed the type I-E 
system from E. coli (78).  The resolution was poor but clearly showed that the Cse1 sub-unit was the 
point of recruitment for Cas3.  TfuCas3’s crystal structure was solved the same year and associated 
13 
 
biochemistry shows that the linker-helix motif of Cas3 is important for the recruitment of Cas3 to 
Cascade (69).  Hayes et al. showed a more complete picture of target binding, using a partially double-
stranded target (55).  It revealed the PAM recognition elements as well as defined a conformational 
change in the Cse1 sub-unit C-terminal domain that would prove significant in Cas3 binding and 
validation of target recognition.  Another set of cryo-EM structures using T. fusca Cascade showed 
partial- and full-R-loop formation on a full-length double stranded substrate (58).  It shows 
conformational change mechanisms that signal Cas3 recruitment in more detail as well as hint towards a 
mechanism that helps Cas3 initial cleavage by bulging the non-target strand towards the expected site 
of Cas3’s nuclease center.  It also identified a series of salt bridges between Cse2 and Cas7 that are not 
present in E. coli.  These salt bridges close over the target strand-crRNA duplex, locking it in place, but 
these interactions also increase the thermal requirement for target binding.  Xiao et al. 2018 describes in 
more detail the Cas3/Cascade interface surfaces and provide residue-specific interaction mechanisms 
(57).  These structures also show that the initial nicking of the substrate DNA occurs through direct 
interaction with the nuclease center, and the nicked substrate is only threaded through the helicase 
afterwards.   
Cas3 itself is the nuclease that degrades DNA in the Type I-E system (69, 79, 80).  It is comprised of a 
nuclease-helicase fusion and translocates processively along DNA in a 3’ – 5’ direction (Figure 1.3).  The 
helicase is a SF2 family helicase with two RecA domains that work cooperatively to move along the 
substrate DNA.  This translocation happens in three nucleotide bursts in E. coli (81).  Other single 
molecule work has shown that Cas3 seems to have two modes of activity (82, 83) (Figure 1.4).  In the 
first, it is recruited to Cascade specifically, making the initial nick and reeling the substrate DNA.  This 
loops out the target strand since Cas3 is still bound to Cascade which tethers the supercomplex to the 
target site.  The non-target strand is intermittently cleaved and some sections re-anneal after passing 
through the helicase, generating sections of double- and single-stranded DNA.  In the second mode, 
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Cas3 has released from Cascade and translocates independently.  TfuCas3 has been shown to have a 
highly processive helicase, capable of translocating over 10kb away from the Cascade targeting site (83).  
There have been some hints that the cleavage products of Cas3 have some form of sequence preference 
or might be involved in spacer biogenesis during CRISPR adaptation, though further studies are required 
(84, 85). 
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Figure 1.3: Cas3 structure and mechanism of target degradation. a) Domain organization of the Type I-E 
Cas3 nuclease-helicase.  The HD-nuclease (teal) contains two divalent metal ions (red); the SF2 Helicase is 
comprised of two RecA domains (two shades of blue); and the Linker Helix and C-Terminal Domain (gray).  The 
substrate DNA (orange) is threaded through an opening between the C-terminal domain and the helicase, along a 
substrate groove, and fed into the nuclease active site (adapted from the structure in Huo et al. 2014). 
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Figure 1.4: Steps of DNA interference in Type I-E CRISPR.  1)  PAM recognition occurs mediated by 
contacts between the Cse1 sub-unit and the substrate DNA.  If the PAM sequence (Purple) is not 
validated, the Cascade complex will dissociate from the substrate.  2)  If the PAM sequence is verified, 
direct base-pairing between the substrate and the crRNA form an R-loop.  If base pairing is not validated 
to a sufficient degree, the R-loop collapses and Cascade dissociates from the substrate.  Once proper 
recognition between the crRNA and the substrate occurs, a conformational change locks the substrate in 
place.  3)  Cas3 associates to the full formed R-loop, with the nuclease domain oriented towards the 
looped-out single-stranded DNA.  4)  A nick is produced on the looped-out DNA at approximately the 9th 
position from PAM.  5)  Cas3 loads the substrate through the helicase domain, probably by threading.  6) 
In the first mode of activity, Cas3 remains associated to Cascade as it reels the DNA, producing a loop of 
DNA on the target strand which consists of a mixture of single and double-stranded DNA.  7)  In the 
second mode of activity, Cas3 dissociates from Cascade and translocates independently.  It is possible 
that double strand breaks are formed at some points during this step.  
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Huo et al. revealed that the preferred divalent ion for the active site of tfuCas3’s HD nuclease domain 
was Co2+ for in vitro cleavage (69).  When solving the crystal structure, the protein was recombinantly 
expressed in E. coli in LB media.  The resulting structure shows two iron ions in the active site of the 
nuclease.  Unfortunately, this iron-loaded tfuCas3 is not very active and requires a very high 
concentration of Cobalt for in-vitro cleavage assays and requires high temperature cleavage conditions.  
This suggests that the metal ion at the active site is held very strongly by electrostatic interactions with 
the nuclease domain, making later replacement of the active site ions inefficient.  To get around this I 
expressed tfuCas3 in M9 media lacking a metal supplement, adding Cobalt at the induction of expression 
(Chapter III).  This resulted in a drastic increase in activity, even when cobalt was left out of the in-vitro 
cleavage buffer.  However, it is not conclusive that cobalt is the native metal ion for T. fusca cas3 in the 
host bacteria.  Instead it is possible that Fe2+ is indeed the native ion, but in recombinant conditions 
iron is quickly oxidized to Fe3+3. 
1.5 CRISPR Adaptation 
As an adaptive immune system, CRISPR arrays must contain a mechanism to update the library of 
targeted sequences in response to invasion.  This process is not as well understood as CRISPR 
interference, with several outstanding questions such as the mechanisms of spacer biogenesis, primed 
adaptation, and the details of spacer insertion into the CRISPR array. 
Most, if not all, CRISPR systems rely on a conserved pair of proteins, Cas1 and Cas2, as the core of their 
adaptation machinery (86, 87).  These proteins form a complex with 4 copies of Cas1 and two copies of 
Cas2 (Figure 1.4a).  The arrangement of this complex is in a “dumbbell”, with two Cas1 dimers bridged 
by a dimer of Cas2 (21).  Cas1 contains a nuclease site, giving the overall complex a total of four 
nucleases (88).  The size of the complex acts as a “ruler” to measure the length of a spacer via non-
                                                          
3 Personal communication. 
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specific contacts to the substrate DNA (89).  Integration into the crArray occurs at the site of the first 
repeat, which is next to a sequence called the Leader (34) (Figure 1.4b).  This Leader determines the 
orientation of insertion, since orientation is vital to proper CRISPR interference from the resulting crRNA 
(23).  Upon integration, the first repeat is split into two complementary regions which remain base-
paired but that bridge the leader to the spacer and to the rest of the crArray (90).  In some systems, the 
Cas1-Cas2 complex is sufficient for integration into a crArray, host factors are required in others (23).  
Through a mechanism that is not fully understood yet, the repeat regions are repaired, resulting in 
copying of the repeat, integration is complete, and the crArray is expanded to include a new spacer (91).  
In some Type II CRISPR systems, an additional component is required for spacer acquisition but is 
seemingly not involved in integration, Csn2 (92, 93).  This protein is a tetramer and has a putative 
function in spacer processing prior to integration.  There is evidence to suggest that it bridges Cas1/Cas2 
to Cas9 and serves to bring the whole complex together during acquisition and Cas9 likely plays a role in 
integration target selection (94). 
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b) 
 
 
Figure 1.5: Cas1/Cas2 organization and model of spacer integration. a) Cas1-Cas2 structural organization 
shown as a crystal structure (left) and schematic (right).  Cas1 sub-units are shown in Gray and Black, Cas2 subunits 
are shown in blue.  Substrate spacer DNA is shown in orange.  The complex is organized as two dimers of Cas1 
bridged by a dimer of Cas2 (adapted from the crystal structure in Xiao et al. 2017). b) Schematic representation of 
integration intermediates during Cas1/Cas2-catalyzed spacer integration.  Cas1/Cas2 recognizes the leader 
sequence and binds to the repeat immediately adjacent.  Next, it catalyzes integration such that the new spacer is 
ligated to the repeat at the 5’ ends, resulting in a duplication of the repeat sequence after an uncharacterized 
repair event.  
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Through a mechanism not fully understood, all spacers that are integrated into crArrays contain 
interference PAMs adjacent to their target site in the invader genome.  This ensures that interference is 
possible against the target site.  There is some speculation in the literature that Cas1/Cas2 contains a 
PAM recognition motif, but the evidence for this is not complete (89).  There is, however, another 
mechanism that compensates for the possibility of escape mutations at target sites of invader genomes.  
This mechanism is called Primed Adaptation or Primed Spacer Acquisition.  In this process, a partially 
mismatched target sequence or a mutated PAM sequence can trigger the acquisition of new spacers at a 
higher rate than naïve adaptation (84).  This process is Cas1/Cas2, Cascade, and Cas3-dependent in the 
Type IE system, but the detailed mechanisms are not understood (95).  In the Type I-E CRISPR system, 
RecBCD helicase activity is a requirement for naïve adaptation (96).  RecBCD is a nuclease-helicase 
complex capable of moving in both 5’-3’ and 3’-5’ directions with two separate helicase domains (97).  It 
has been speculated that Cas3 might be fulfilling a similar role to that of RecBCD in the selection of pre-
spacer substrates for Cas1/Cas2 during primed adaptation (85). 
1.6 CRISPR Applications 
An intense focus of CRISPR research has been the development of new molecular biology technologies.  
As an indicator of this trend, many basic science CRISPR research articles tend to have passages in the 
discussion section which propose possible implications or technologies that might arise from the 
research.  Most CRISPR-based technologies rely heavily on the principle of RNA targeting and how easy 
it is using CRISPR/Cas to target unique and varied sequences with a protein effector, relative to other 
existing technologies.  These technologies take the form of direct substrate cleavage or modification as 
well as co-localization and imaging.  Nucleic acid detection has also been explored through CRISPR 
technologies that enable novel approaches with high sensitivity. 
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Genome Editing 
Cas9 and other single-component effector complexes are natural gene editing tools.  They are highly 
programmable in a way that other gene editing technologies have not been traditionally.  For instance, 
in order to induce a double-strand break at a specific site, one could employ a restriction enzyme, of 
which there are many high-fidelity engineered nucleases available.  However, due to the targeting size 
(typically 6-10bp), in a large genome such as a mammalian genome, there are inevitably redundant sites 
and it is unlikely that a restriction enzyme exists for your desired target site.  Meganucleases are along 
the same vein and go partway to solving the specificity problem but again are limited in the sequences 
that they can target.  Alternatively, using TALENs creates a much more highly specific system, but they 
require a lot of cloning steps to assemble the domains in the correct order to confer specificity. 
In comparison, Cas9 is extraordinarily simple to use.  An end-user of a CRISPR technology typically only 
needs to make minor considerations regarding their target site, such as the presence of a PAM nearby.  
And, given the small size of the PAM requirement, PAMs are not a rare occurrence.   
Cas9 genome editing technologies have been applied to a wide range of targets, cell types, and 
organisms.  The first editing studies were conducted in cancer cell lines by both Zhang (Cong et al.) and 
Doudna labs (Jinek et al.) both published in January 2013 (36, 98). Subsequently, mutant mouse 
generation quickly followed (99).  Since then, Cas9 editing has been performed on primary cell lines, 
embryos, and in various model organisms from Drosophila to Zebrafish.  Derivative technologies have 
been developed that utilize the CRISPR/Cas9 platform and accelerated the trajectory of progress in the 
biological sciences.  These other technologies involve screening applications for multiplexed gene 
editing; active domain fusions to localize biochemical activity to a target site; engineered genetic 
elements called “gene drives” which can theoretically push evolution uphill by forcing the fixation of a 
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detrimental allele.  All of this was possible from the development of a single editing platform.  The 
availability of other platforms might help this process to develop even further. 
Engineering Strategies 
Modifications to the natural CRISPR/Cas machinery help to expand the capability or the ease of use for 
CRISPR/Cas-based technologies.  These approaches fall under three main umbrellas: simplification of the 
system, improved fidelity, or expanded PAM recognition.  In these, the simplification of the Cas9 
machinery was accomplished by creating the single-guide RNA.  This is a fusion of the tracrRNA with the 
crRNA at the end of the stem that mediates the tracrRNA/crRNA interaction in the natural case.  This 
modification allows a single transcription unit to encode the entire Cas9 guide (66). 
Further modifications directly to the Cas9 protein have been performed to increase the fidelity of the 
enzyme in its target recognition.  This has generally been accomplished through mutations that slow 
down the conformational change during the target recognition step, causing the active conformation to 
be less favored during off-target recognition events (100, 101).  This is important because conclusions 
have been murky when it comes to the off-target effects of Cas9 activity, with studies going back and 
forth, being published and retracted alternatively.  As of yet, I would not say there is a well-settled 
conclusion of off-target activity for in-vivo CRISPR/Cas target recognition or a full characterization of the 
nature of unintended editing events (102-108). 
In the pursuit of unique activity or in reducing off-target effects, there are many ways to achieve more 
favorable biochemistry.  If a structure or enough structural information exists to perform rational design 
engineering, this can speed the process along greatly.  In the most basic example, in using Cas9 as a 
targeting platform without any need of the nuclease activity, single point mutations at the nuclease 
reaction centers were performed (109-111).  Along these same lines, deactivating only one nuclease site 
or the other can be used to generate a gentler nickase as opposed to a double-stranded endonuclease 
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(112-114).  In more complicated scenarios though, there are many mutations or modifications that exist 
which might assist towards the goal but are not immediately obvious.  For this reason, homologue 
screening and directed evolution are two methods which can provide a framework for success. 
Homologue screening strategies have primarily been employed as a means to expand the library of PAM 
sequences that are targetable by CRISPR-based genome editing strategies.  While PAM sequences are 
common in most genomes, the availability of a PAM site at a specific locus limits the precision of editing 
technologies. If an expanded library of CRISPR/Cas systems exist, it inherently expands the availability of 
target sites, since PAM sequences are not entirely conserved across diverse CRISPR systems.  For 
instance, the N. meningitides Cas9 has a NNNNGATT PAM (115).  The increased length of the N. 
meningitides Cas9 PAM decreases the frequency of a PAM site, but also theoretically decreases off-
target effects, and is compatible with lower-GC content regions of the genome (116, 117).  Additionally, 
the exploration of other CRISPR systems with different biology entirely can move the field forward.  The 
more recently discovered Cas12 of the Type V systems is one such exploration, with its development still 
in the early stages (118).  Instead of generating a blunt double-strand break, Cas12 (previously Cpf1) 
generates 5 nucleotide 5’ overhangs after target validation, similar to more traditional restriction 
enzymes commonly used for cloning.  Cas12 recognizes PAM through contacts on both the major and 
minor groove, but the PAM identity is very different (Cas9: NGG, Cas12: NTTT) and recognition occurs on 
the opposite side of the target site compared to Cas9 (64).  Cas12 has a distinct potential advantage in 
that the crRNA does not require a tracrRNA and Cas12 is capable of processing its own crRNA whereas 
Cas9 requires other processing factors (119).  However, when Cas12 binds to a cognate target substrate, 
the protein’s nuclease behavior is not only localized to the target site, but instead acts seemingly 
indiscriminately on all nearby ssDNA substrates (120).  This has largely halted the development of Cas12 
as a gene editing platform. 
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Directed evolution strategies employ an artificial selection mechanism to achieve a desired biochemical 
activity.  The basic principle is that a library of candidate constructs (generally produced through random 
mutagenesis) are generated and the relative abundance of the members of this library undergoes a 
selection scheme (121).  For instance, in selecting for a more active protein, Hu et al. employed a design 
whereby a library member’s improved ability to survive phage infection resulted in a higher 
representation in the population of host E. coli used to conduct the experiment (122).  After selection, 
PAM specificity could be altered from NGG to include NG, GAA, or GAT. 
Nucleic Acid Detection 
The ability to reprogram CRISPR/Cas systems to target any arbitrary nucleic acid makes them attractive 
for nucleic acid detection platforms.  These systems would be useful in diagnosis of viral diseases when 
viral loads are small or to differentiate between different but related viruses.  Furthermore, some 
CRISPR/Cas systems, such as Cas13 of the Class 2 Type VI systems or Cas12 of Class 2 Type V, exhibit 
non-specific and rampant collateral trans-cleavage of other nucleic acids (120, 123).  The generalized set 
of technologies involves Cas13 or a CRISPR system capable of indiscriminate cleavage upon target 
binding in solution with a sample of nucleic acids and a reporter fluorophore linked to a quencher.  
When Cas13’s cleavage activity is activated by binding to a target, the fluorophore reporter is cleaved 
through non-specific activity and increases the fluorescent signal in solution.  This approach is capable of 
approaching atto-molar sensitivity since a single activated Cas13 protein can cleave many fluorophore 
reporters and thereby amplify the signal to the detection threshold (124, 125).  Similar technologies 
have been developed based on Cas12 (125-127). 
Domain Fusions 
Due to CRISPR/Cas technologies being so flexible in their programmable targeting, they are attractive 
scaffolds to be used in delivering protein domain payloads with biochemical activity to defined nucleic 
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acid sequences with a high degree of specificity.  This can be accomplished by designing domain fusions 
of enzymes or other epitopes that confer novel functions to the Cas machinery.  Most often, this is done 
with catalytically dead Cas9 (dCas9). 
Epigenetic modifiers or transcriptional regulators are a common domain fusion (128-130).  One of the 
first non-genome editing approaches developed for the dCas9 platform is the technique known as 
CRISPR Interference or CRISPRi (111, 131).  This CRISPR interference is separate and apart from the 
interference discussed in general CRISPR mechanisms, wherein DNA degradation is the mechanism of 
interference, though they share the same name.  Instead, the term is meant to draw an analogy to the 
genetic tool of RNAi, wherein exogenous short RNAs are used to mediate mRNA cleavage and thus 
expression repression.  In CRISPRi, transcriptional repressor or activator domains are fused to dCas9, 
thus allowing artificial transcriptional control at a target promoter.  This can be used to increase or 
decrease the expression of a target gene to observe how modulation effects cellular processes, or it can 
be used to artificially bring a transcription factor to a promoter of a reporter gene to measure the effect 
a particular factor has on transcription. 
An application that is much needed in the field of genome editing is the ability to precisely and 
specifically modify a base to a desired identity.  To address this, cytidine de-aminase has been fused to 
Cas9, conferring the ability to de-aminate substrate cytidine, resulting in a transition to a uridine base 
(132-135).  This uridine is then repaired to a thymine by repair mechanisms which excise and replace 
DNA uridine with thymine (136).  Since this modification can occur on either strand, G->A modification is 
also possible and thus it allows a not insignificant range of editing targets.  This activity is not as yet 
specific enough to modify a single base and only a single base, but it highlights how much closer the 
engineered tools are to solving these problems. 
Precision Medicine 
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One of the most anticipated applications of precision gene editing has been the modification of a 
patient’s own stem cells or the editing of patient-derived induced pluripotent stem cells.  This 
application has the potential to treat a slew of genetic disorders which affect a subset of tissues due to a 
mutation, such as many blood diseases (hemophilia, sickle-cell, etc.) (137, 138).  Individual genetic 
surgeries can repair the mutant gene to an active form in cell culture and the edited stem cells can then 
be returned to a patient by transplant (139, 140).  There, the edited cells will differentiate, creating 
healthy tissue in which the deficiency has been corrected.  Using a patient’s own stem cells or patient-
derived induced pluripotent stem cells reduces the risk of graft rejection and greatly reduces the risks of 
therapy (141).  This approach has seen promising results in rescuing even otherwise lethal mouse 
models of disease and phenotype corrections have been observed in cell-culture of patient-derived 
primary cell lines (142-147).  Clinical trials of these procedures are upcoming and present an exciting 
synthesis of both induced pluripotent stem cell technologies and CRISPR gene editing. 
Cas9 for Large Deletions 
Using Cas9 for deletions of gene targets are usually accomplished through introducing point mutations 
at the target site via repair processes that introduce frame-shifts to the coding sequence (148).  This is 
useful for many applications from developing disease models, functional genomics investigation, and 
even the potential rescue of dominant-negative disease phenotypes.  However, there are a number of 
applications where frame-shift mutations or other small mutations are not sufficient to cause the 
desired effect, such as when investigating regulatory sequences, enhancers, or tandem repeat regions of 
the genome.  For these applications, one needs to fully delete the whole genomic locus that comprises 
the element of interest.  This can be done with Cas9 approaches, such as dual-targeting with two Cas9 
guides.  This however, has a low efficiency compared to standard editing, and the larger the region to be 
deleted, the lower the efficiency is (149-151).  This has consequences in modeling cancer genetics, since 
many cancer phenotypes are caused by large genomic deletions (152-154). 
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Type I CRISPR Technologies 
In this thesis, I describe a novel technology based on the Type I-E CRISPR system of T. fusca.  Though it is 
the first technology to utilize the type I system outside of bacteria to which those systems are 
endogenous, it is not the first technology or technique developed.  
The earliest technologies to utilize the Type I CRISPR system were as a CRISPRi platform.  CRISPRi is a 
technology originally developed using a catalytically inactive Cas9 which utilizes a guide sequence 
against either a coding region of DNA or a promoter element to cause a repression of transcription in 
that region (131).  This is achieved either through direct obstruction of the DNA by the bound CRISPR-
cas complex or by a fused repressor domain.  Since this technology does not require anything more than 
the Cas proteins and a provided targeting crRNA expression cassette, it is possible to re-purpose existing 
CRISPR systems in endogenous host bacteria for CRISPRi strategies.  This was performed by both Luo et 
al. 2015 and Rath et al. 2015, where both used the E. coli Type I-E system (155, 156).  Both approaches 
utilized a Cas3-knockout strain so that target recognition by the endogenous Cascade complex would 
not result in target cleavage.  In both cases, the authors introduced the crRNA through plasmid 
transformation and observed repression whether Cascade targeted the coding region or the promoter 
of a reporter gene.  Both papers observed that the effectiveness of repression depended on the strand 
that Cascade was bound to, but their results were conflicting.  Rath et al. 2015 found that targeting the 
template strand of their GFP reporter resulted in more repression (155).  Luo et al. 2015 found that 
targeting the non-template strand resulted in stronger repression, which is the same observation that 
has been made for dCas9-based CRISPRi technologies (156).  Overall, since Type I CRISPR-system 
containing bacteria represent a majority of those bacteria with any CRISPR system at all, the ability to 
use the native Type I system as an investigative tool expands the capabilities of researchers who work in 
non-model organisms (30). 
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 The only other genome engineering technology that exists using Type I CRISPR systems is that which 
was developed by Li et al. 2016 (157). They developed a method that uses the CRISPR systems native to 
Sulfolobus islandicus to enforce genetic selection for desired knock-in or knock-out mutations.  Their 
design relied on the delivery of a plasmid which contained a donor DNA sequence with homology arms 
for the mutation target site and a minimal crArray which targets the un-mutated genomic site.  The 
crArray in the plasmid gets transcribed and is then loaded to either the Cmr or Cascade complex.  If 
homology directed repair did not occur, the CRISPR system binds the genomic locus, causing 
chromosomal degradation and destruction of the host genome.  This means that the vast majority of 
surviving cells are the result of homology directed repair.  In this way, the CRISPR system can be said to 
be used more as a mechanism for negative selection rather than as a true genome editing tool. 
In this thesis, I describe the first true genome editing technology that uses any Type-I CRISPR system.  In 
human embryonic stem cells, the use of Cascade and Cas3 generates large genomic deletions with 
variable start sites, variable end sites, and variable sizes.  Cascade is tagged with Nuclear Localization 
Signals (NLS) on the C-terminal end of Cas7, Cas3 is also tagged with NLS on the C-terminal end.  Cascade 
is co-expressed along with crRNA guides that target a genomic locus.  When delivered via 
electroporation, the system introduces directional deletions in the expected direction of Cas3 
translocation.  These deletions seem to often be scar-less, with no inserted nucleotides resulting from 
the repair mechanism detected in the deletions that were analyzed by sequencing.  While the start, 
stop, and length of deletion cannot be controlled at this time, this application allows for the creation of 
large genomic deletions with a single guide RNA.  In E. coli and T. fusca Type I systems, both AAT and 
AAG are interference PAMs due to the promiscuous nature of Cascade PAM recognition (158).  These 
PAMs are both compatible with low-GC regions of chromosomes, unlike the NGG Cas9 PAM.  This could 
be relevant because the human genome has 100kb stretches that range in GC content wildly with an 
average of 41% GC (159).  Even though interference for AAT is measured as lower than AAG for T. fusca 
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in an interference assay, Cas9 is unable to target any site that lacks a GC pair – even with extensive 
engineering to alter PAM specificities (69, 160). 
In the following chapters of my thesis, I will discuss three lines of investigation.  In the first I discuss 
mutational analysis of the Cas3-Cascade interface and how it suggests a complex mode of interaction 
during the recruitment of Cas3.  In the second, I describe a genome editing technique we developed that 
uses the Type I-E CRISPR system from T. fusca to generate long genome deletions in eukaryotic cells.  In 
the third, I outline a model to describe the mechanism of Cas3-induced double strand breaks via 
dimerization of Cas3 independent of Cascade. 
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2.1 ABSTRACT  
CRISPR (clustered regularly interspaced short palindromic repeats) loci and the nearby CRISPR-
associated (cas) operon provide bacteria and archaea with an RNA-based immunity system against 
foreign genetic elements. In Type I CRISPR-Cas systems, the crRNA-containing Cascade complex 
generates an R-loop structure in the matching region of a foreign dsDNA, and subsequently recruits the 
nuclease-helicase fusion enzyme Cas3 for processive DNA degradation. Despite multiple efforts, a clear 
definition of the Cascade and Cas3 interaction remained at low-resolution. Here I show that site-
directed mutagenesis around the Linker helix of Cas3 (residues 779-797) perturbed its binding with 
Cascade. Whereas some mutants led to losses in both Cas3-binding and DNA target cleavage, others 
enhanced Cas3-binding, but abolished DNA cleavage. These different behaviors suggest an unexpected 
complex mode of Cascade-Cas3 interaction. I speculate that in addition to the direct physical interaction 
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mediated by the Linker helix of Cas3, the conformational state in the helicase of Cas3, and the relative 
orientation between Cas3 and Cascade, may play important roles in Cas3 recruitment and activation.  
2.2 INTRODUCTION 
Nearly 50% of bacteria and 80% of archaea organisms maintain the Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR) and the associated cas operon nearby to provide an RNA-based 
adaptive immune system against foreign nucleic acids in bacteriophages and conjugating plasmids (161-
163).  CRISPR associated proteins (Cas proteins) utilize the processed CRISPR RNA (crRNA) as a guide to 
mediate surveillance for, interference against, and acquisition of foreign nucleic acid molecules (161-
164).   CRISPR systems are further classified into types based on the signature proteins in their cas 
operons; each type uses a distinct interference mechanism (165).  Type I CRISPR system accounts for 
90% of all naturally occurring CRISPR systems. It contains the signature protein Cas3, and can be further 
categorized into six subtypes based on distinctive features in the cas operon (Type IA – IF) (165). 
Organisms such as E. coli and T. fusca utilize the Type I-E CRISPR system, which employs a CRISPR-
associated Complex for Anti-viral Defense (Cascade) to search for dsDNA targets matching the spacer 
region of the CRISPR RNA (crRNA) (51, 166, 167).  The Type I-E Cascade consists of a crRNA guide and 
eleven protein subunits from five Cas proteins (Cse1 (1), Cse2 (2), Cas5e (1), Cas6e (1), and Cas7(6), and 
CRISPR-derived RNA) (168, 169).  Upon encountering a matching dsDNA adjacent to an optimal PAM 
(Proto-spacer Adjacent Motif) sequence, Cascade initiates the DNA unwinding process, promoting 
segmented base-pair formation between the crRNA spacer and the target DNA strand (55). This loops 
out the non-target DNA strand, giving rise to an R-loop structure (78). The Cascade-marked R-loop 
structure recruits the signature protein Cas3, which is a fusion of an HD nuclease and a super family II 
helicase (69). Upon binding, Cas3 nicks the non-target DNA strand ~7-12 nucleotide downstream of PAM 
and processively degrades the non-target strand and target strand DNA in a sequential fashion (170). 
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The sequential activation of target searching and degradation machines in Type I CRISPR systems may 
provide higher selectivity to the system.   
How does Cas3 selectively bind to the R-loop forming Cascade, while avoiding the free Cascade? The 
mechanism remained poorly understood despite intensive biochemical dissection and structure-
function analysis. In a low-resolution reconstruction of the Cascade-Cas3 complex, residual Cas3 
densities were found on top of the Cse1 subunit of the Cascade (78). The resolution of this EM 
reconstruction precluded detailed dissection of molecular interactions. A high-resolution crystal 
structure of the T. fusca Cas3 has been determined, and its interaction with the T. fusca Cascade 
reconstituted (69). In subsequent mutagenesis experiments, it was shown that deletion of the linker 
helix in Cas3 (residues 779-797) resulted in a complete loss of Cascade-Cas3 interaction in vitro, and a 
loss of CRISPR interference function in vivo (69). 
To further dissect the Cascade-Cas3 interaction, we performed manual docking of the T. fusca Cas3 
crystal structure into the E. coli Cascade structure bound to a partial R-loop (55).  Based on this model, a 
series of mutations along the Cas3 linker helix were designed and their effects on Cascade binding and 
DNA target cleavage were examined.  Mutants were assessed for Cascade binding via EMSA and 
Cascade-mediated DNA cleavage activity via denaturing PAGE.  We identified multiple mutants which 
affected defects in both assays and one mutant which surprisingly showed an increase in Cascade 
binding but abolished DNA cleavage.  We were able to narrow down one point mutant in a region just N-
terminal to the Linker Helix on the surface between the two Helicase domains which demonstrated a 
Cascade affinity defect. 
2.3 RESULTS 
Besides our understanding that Cas3 binds to the vicinity of Cse1 subunit of Cascade, little was known 
about the detailed molecular interaction. Our structure-function analysis of Cas3 identified its linker 
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helix as a key structural element mediating the Cascade-Cas3 interaction (Figure 2.1a) (171). We 
therefore attempted a few manual docking exercises, assuming the linker helix is a major element at the 
interface.  The Cascade structure model we generated is primarily composed of the E. coli partial R-loop 
crystal structure (55).  We then replaced the Cse1 component of this structure with a homology 
modelled T. fusca Cse1 (172). 
This model makes several assumptions that were supported by the known mechanisms of Cas3-
mediated target degradation as well as by density shown in the published low-resolution Cas3-Cascade 
EM map (78).  First, the orientation of Cas3 must agree with its direction of movement on the non-target 
DNA strand, hence the helicase is facing the PAM-proximal region. Second, the HD nuclease of Cas3 
must be able to reach the non-target strand DNA 9-12 nucleotides downstream of PAM, assuming this 
DNA strand remains flexible in the R-loop region (78, 170).  Third, because Cas3 only binds to the R-loop 
presenting Cascade, we assume the Cas3-binding interface must span an area in Cse1 that undergoes 
conformational changes during the R-loop formation process (55). These assumptions led to a manually 
docked model where Cas3 docks its Linker helix into a shallow groove in Cse1.  This manually docked 
model agrees closely with the later-determined high resolution cryo-EM structure of Cas3 bound to 
Cascade (Figure 2.1b) (57). The model was not generated in a systematic fashion, and it requires the 
non-target DNA strand to deviate from the true path slightly to access the Cas3 HD nuclease center. It 
was nonetheless very helpful in guiding the focus of the regions to target and our initial design of Cas3 
mutants (Figure 2.1c). 
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a) 
 
b) 
 
c) 
 
 
Figure 2.1: Structural overview of Cas3-Cascade interface.  a) Overall Cas3 structure with linker helix 
interface residues investigated in this study.  AA766-770 (Region 1) in red, AA776-787 (Region 2) in blue, AA791-
797 (Region 3) in magenta. b) Structural model of cascade-Cas3 association (from Xiao et al. 2018) (57).  c)  Zoom-
in of the linker helix, showing interacting residue orientations.  Interaction between D766 and H487 shown in the 
inset. 
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2.3.1 Region Mutations 
Two rounds of mutagenesis were carried out to narrow the mutational effects from the entire Linker 
Helix region to single amino acid residues. The helix deletion was first divided into three smaller 
deletions, covering a region just outside the helix to the N-terminal side, the N-terminal end of the helix, 
and the C-terminal section of the helix (Figure 1c).  The mutants were assayed for Cas3-binding defects 
using electrophoretic mobility shift assays (EMSA) and Cas3-mediated DNA cleavage defects analyzed by 
denaturing PAGE.  
In the EMSA experiments, increasing concentrations of Cas3 were added to Cascade bound to a 
fluorescent substrate in a pre-locked R-loop conformation.  Comparisons were made between the 
mutant cas3 affinity for this Cascade-Substrate complex and the wild-type affinity.  A loss of the up-
shifted band which results from Cas3 binding is interpreted to be the result of a disruption of the Cas3-
Cascade interaction. 
In the DNA cleavage experiments, Cas3 mutants were assayed for their ability to degrade substrate DNA.  
Again, the Cascade was pre-loaded with fluorescently labelled substrate.  Cas3 was then added to this 
complex and heated to a reactive temperature (58C) in the presence of excess Cobalt and ATP.  Wild-
type Cas3 degrades the substrate in a dose-dependent manner.  Since Cas3 is only able to degrade 
double-stranded DNA when recruited to a fully R-looped Cascade, this is an indirect read-out for Cas3’s 
ability to associate to Cascade in a functionally relevant manner.  The processive cleavage products of 
the mutants were visually assessed for cleavage efficiency compared to wild-type. 
Those mutants which had five or more amino acid substitutions were included in the category of Region 
Mutations.  These regions were AA 766-770 (covered as the mutant called “Region 1” – this region is 
outside the Linker Helix at the N-terminal end), 776-787 (covered in the mutant “Region 2” – this region 
is comprised of residues at the N-terminal end of the linker helix), and 791-797 (“Region 3” at the C-
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terminal end of the linker helix) (Table 2.1).  The Region 1 and Region 2 (766-770 and 776-787) were 
targeted as glycine mutations because they were outside of the helix, presenting looping structures 
along the surface of Cas3.  In Region 2, an arginine was chosen to replace an aspartic acid at position 
781 because of an interaction with R742 of the Helicase domain, with the logic being that this would 
affect a maximal disruption.  Region 3 was a standard alanine scan substitution.  Region 1 and Region 3 
present an easily interpreted binding and cleavage defect – we believe it is clear that these mutants are 
disrupting binding and thus severely affect cleavage (Figure 2.2).  Region 2, however, displays a 
phenotype of increased binding in EMSA.  Surprisingly, despite this result, the cleavage phenotype for 
this mutant is as severe as the most severe cleavage defects (Figure 2.2). 
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Table 2.1:  Summary of Cas3 mutants and their effects on biochemistry.  Amino Acids mutated, given 
names for the paper, effects on binding, and effects on cleavage. 
 
Mutant AA Mutated Binding Cleavage 
  Wild Type / + + 
  Region 1 D766G, D767G, D770G, D771G, D772G - - - - - - 
    D766A D766A - - - - - 
   770-772 D770A, D771A, D772A - - - - - 
  Region 2 E776G, D777G, D781R, E783G, R784G ++ - - - 
    776-779 E776A, D777A, L778A, E779A - - - 
   781-784 D781A, M782A, E783A, R784A - - - 
  Region 3 
Q791A, R792A, L794A, A795G, R796A, 
N797A 
- - - - - 
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a) 
 
b) 
 
c) 
 
Figure 2.2:  Cas3 Region mutants data for Region 1, Region 2, and Region 3.  (a) Agarose native gel 
showing Cascade-bound substrate (†) and Cas3-Cascade-bound substrate (*) over Cas3 titration scanned for 6FAM, 
quantified in (c) (b) Urea dPAGE cleavage experiment on the same substrate as (a) showing nick and processive 
cleavage products in the presence of ATP.  All mutants show no significant cleavage products. (c) quantification of 
native gel showing significant binding defects for Region 1 and Region 3 mutants.  Surprisingly, Region 2 shows an 
increase in binding, but abrogation of cleavage (b).  
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From these results, we can make a few preliminary observations and predictions.  The residues at the 
most N-terminal end of the linker helix are not directly involved in a specific binding interaction since 
the Region 2 mutant exhibited strong binding to Cascade in vitro but no detectable cleavage activity on 
DNA substrates.  This conclusion is supported by the high-resolution Cryo-EM structure (57).  The 
mutant at the C-terminal end of the helix (Region 3) is more readily interpretable in these results since 
mutation resulted in coupled binding and cleavage defects.  We could also start to form a hypothesis 
that the helicase may be important for proper Cas3 binding in the Region 1 mutant.  However, from 
these experiments alone, it is not possible to determine whether this restriction on binding is due to 
modification of the binding surface or due to restriction of a necessary conformation in the helicase. 
2.3.2 Specific Mutations 
To further investigate key residues and the important features of Cas3 which are necessary for 
association to Cascade, the above region mutants were split into smaller, more targeted sections. The 
conserved negative charges were specifically targeted based on the hypothesis that the Cascade-Cas3 
interaction may be mediated by favorable electrostatic interactions. Region 1, which is outside of the 
Linker Helix to the N-terminal end, was split into a point mutation at residue 766, substituting alanine 
for the aspartic acid at that position.  Additionally, another mutant covering the stretch of aspartic acid 
residues along the surface of Cas3 at AA 770-772 was generated as three alanine substitutions.  
Additionally, these negative residues make a number of favorable interactions with positive residues 
from each of the helicase domains (H487 and R749).  In our assays, 770-772 and D766A elicited severe 
phenotypes in both binding and cleavage (Figure 2.3).  D766A is the only point mutant to show a 
phenotype, with no detectable binding or cleavage whatsoever. 
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a) 
 
b) 
 
c) 
 
Figure 2.3:  Cas3 mutant data for D766A, D770-772A. (a) native gel (b) cleavage (c) quantification of native 
gel.  Both D766A and D770-772A mutants show a decrease in binding affinity and abrogation of cleavage activity.  
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Another set of targeted mutants included AA positions 776-779 and 781-784 which comprise the N-
terminal section of the Linker Helix.  These two mutants constitute a split of Region 2 and were 
performed as an alanine scan.  Because of Region 2’s surprising characteristics, these mutants are 
necessary for understanding the properties of this segment of the Linker Helix.  Binding and cleavage 
phenotypes for these two mutants were more intermediate than Region 2 (Figure 2.4).  776-779 and 
781-784 still disrupted cleavage considerably, though both had a moderate effect at most on binding.   
In an attempt to extend this information and provide more information on the specific residues involved 
in the interaction surface, single alanine substitutions were performed at various positions on the helix. 
Point mutations at positions R796, N797, L789, E783, M782, E779, E776, and D777 were generated and 
tested, none of which showed an appreciable phenotype in a pilot cleavage experiment (data not 
shown). 
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a) 
 
b) 
 
c) 
 
Figure 2.4:  Cas3 mutant data for 776-779, 781-784. (a) native gel (b) cleavage (c) quantification of native 
gel.  Both 776-779 and 781-784 mutations showed a moderate decrease in binding affinity but an abrogation of 
cleavage activity.  
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2.4 DISCUSSION 
In mutating Cas3, the resilience of the interaction to disruption by point mutation along the Linker Helix 
reflects a complex interaction all along the length of the Linker Helix such that disruption of any 
individual interaction is not sufficient to cause a detectable binding defect.  We have shown some 
mutants which demonstrate only a moderate Cascade binding defect while displaying a severe cleavage 
defect (such as mutations from 776-779 and 781-784).  This implies that there is a set of interactions 
which are required to validate the association of Cas3 through contact signaling between Cas3 and Cse1.  
Alternatively, it may be that the geometry of this interaction is so delicate that disruption of or 
alteration of the orientation in the interaction surface even slightly results in changes to the placement 
of the helicase and/or nuclease domains.  This complex set of interactions would explain well why 
solvent-exposed point mutations along the linker helix are not sufficient to induce binding or cleavage 
defects and may also point toward the specificity of the Cas3-Cascade interaction such that Cas3 can 
only interact with Cascade from the same organism4.  Variability in sequence conservation along the 
linker helix supports this conclusion (Figure 2.5). 
  
                                                          
4 Personal communications. 
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Figure 2.5: Cas3 linker helix sequence alignment.  The linker helix and surrounding region to the N-terminus 
is not very strongly conserved across species which utilize the Cas3-Cascade Type I-E CRISPR system.  The linker 
helix is highlighted in the T. fusca sequence.  D766 (red arrow) is strongly conserved, pointing towards a conserved 
interaction to the RecA domains.  
46 
 
 
In an attempt to use some information gained by the experiments reported here, we performed a series 
of mutations on Cse1 to attempt to perturb the interaction from the other side.  Several targets were 
selected, but in the end through a pilot cleavage screen, none showed a cleavage defect which was 
separable from non-specific substrate binding defects.  Possible targets which we investigated in T. fusca 
Cse1 were R137, R139, R205, R303, and the L3 loop (Y315-P325).  All of these mutations were targeting 
prominent surface features of Cse1 which had solvent exposed positive charges. 
Allosteric Effect of D766A on Cas3 Association 
Based on the high resolution Cryo-EM structure, it is probable that the D766A mutant phenotype is best 
described as an allosteric effect (57).  If there were a cleavage defect only and no binding defect, it could 
effectively be argued that this mutation constitutes a structural mutant which disrupts the activity of the 
helicase.  However, given the direct measurement of binding in the EMSA experiments, it is clear that 
there is a stark binding defect which stands on its own.  The positioning of D766 over the two RecA 
domains of the Helicase lends further credence to this suspicion that it may be altering the surface 
structure (and thus the geometry of residues necessary for binding) or limiting accessibility to a 
necessary conformation for the helicase to bind.  D766 forms a favorable interaction along the surface 
of Cas3 to the backbone amine group of H487, bridging the two lobes of the helicase.  Additionally, 
other aspartic acids in this region form similar interactions with the helicase, such as D770 to H487 and 
D771 to R749.  These interactions may play a role in stabilizing a hinge motion on the helicase in this 
region as a part of a necessary conformational change for Cas3 recruitment and activity.  Based on the 
high level of sequence conservation at this position across Cas3 proteins from different bacteria 
(generally either D or E amino acid identities), we predict that this effect on Cas3 association is a 
conserved general mechanism. 
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Effects of Region 2 on Cas3 Association 
We believe the Region 2 mutant, which affected residues at the N-terminal end of the linker helix, 
displays important and nuanced information on the mechanism of Cas3-Cascade interaction.  Two things 
are true of this mutant phenotype:  Binding still occurs but cleavage is strongly affected.  This result is 
surprising and non-intuitive, but it implies several things.  First, we can assume that most of the residues 
responsible for binding are not largely affected – a conclusion supported by the high resolution Cryo-EM 
structure (57).  We can be relatively safe in our assumption because the severity of the Region 2 mutant 
is drastic in both its scale and in the chemical property changes to that segment of the linker.  We have 
removed four charged residues from this region of the helix and replaced them with glycine while 
simultaneously performing a charge swap in the middle of this region (D781R).  We believe that Region 
2 is not directly involved in binding.  This assumption is supported somewhat by the intermediate 
phenotypes present in the 776-779 and 781-784 mutants in which even the non-solvent exposed 
residues were mutated as well, but binding was not strongly affected relative to wild-type.  These two 
mutants displayed weaker Cascade binding than Wild Type which is surprising.  I predicted that splitting 
this region up should result in an intermediate phenotype between Wildtype and Region 2.  What may 
instead be going on, is that by mutating the residues in Region 2, we have forced the helix to adopt a 
binding-competent conformation constitutively or otherwise have made the binding-competent 
conformation more accessible energetically due to increased flexibility in this region.  One explanation 
for how this conformation change is affected is through the Arginine substitution at position 781 
creating an intramolecular contact with the stretch of Aspartic Acid residues in the span of 770-772 
which is nearby. 
To explain the lack of cleavage in the Region 2 mutant, we propose two possible models.  First, that this 
region is important for either sending or receiving a signal to enact the hand-over of substrate DNA from 
Cascade to Cas3.  In this model, there is a signal sent through a contact in this region to validate the 
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correct association of Cas3 and initiate the dissociation of the DNA target from Cse1.    Afterwards, the 
dissociated target DNA is loaded onto Cas3 for processive cleavage. The fact that both 776-779 and 781-
784 maintain severe cleavage defects while having a smaller mutated range in this region is consistent 
with this model. 
As an alternative explanation, it may be possible that this mutation has introduced a change in the 
orientation of the helix relative to the rest of Cas3 while leaving residues responsible for binding intact.  
This model would explain the lack of cleavage through the nuclease and helicase being out of place 
relative to Cse1 because of the change in orientation on the helix.  If this were true, it still supports the 
conclusion that the linker helix is an important anchor point for a complex Cas3-Cascade interaction. 
MATERIAL AND METHODS 
Cloning:  Cse1, CasB-E, and Cas3 Wild-type coding sequences were amplified from T. fusca whole 
genomic DNA and restriction cloned into pET19b, pCDF and pSUMO respectively with an N-terminal 
strep-tag.  CrRNA was generated as a gene synthesis product and restriction cloned into pRSF.  These 
plasmids were transformed to BL21 competent cells for expression (Cse1, CasB-E, and crRNA triple 
transformed and Cas3 expressed separately). 
Protein Purification:  Terrific Broth (TB - VWR) cultures with antibiotics (Kanamycin: 100ug/mL, 
Ampicillin: 100ug/mL, Spectinomycin: 50ug/mL) were inoculated with 5-25mL of overnight LB starter 
culture and brought up to OD ~0.6 in a 37C shaker.  Temperature was changed to 18C once the culture 
reached desired density, and 1mM IPTG was added to induce expression overnight.  Cells were spun 
down at 4000 RPM, re-suspended in Lysis Buffer (500mM NaCl, 50mM HEPES buffered to pH 7.5 for 
Cas3 and 150mM NaCl, 50mM HEPES pH 7.5 for Cascade), and lysed via sonicator.  Whole cell lysate was 
spun down at 15,000 RPM and the supernatant removed to a separate flask on ice.  Strep resin was 
regenerated using HABA buffer (1mM 2-[4’-hydroxy-benzeneazo] benzoic acid corrected to pH ~8.5) and 
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HABA was eluted with 20mM NaOH.  NaOH was washed off with Lysis Buffer to equilibrate the column.  
Supernatant was flowed over the column and washed three times with 3-4 resin volumes of Lysis Buffer.  
15-20 mL of Elution Buffer (2.5mM desthiobiotin in Lysis Buffer) was flowed over the washed resin 
beads and the flow-through collected.  Protein in Elution Buffer was concentrated in a 10,000 MW spin 
column concentrator to <1 mL total volume and diluted with clean Lysis Buffer without desthiobiotin, 
then concentrated again in the same spin column to a similar volume to remove residual desthiobiotin.  
Concentrated protein was then loaded to an AKTA-pure SD200 SEC Column (GE Healthcare) in Sizing 
Buffer (20mM Tris, 150mM NaCl, 2mM DTT).  Fractions were collected at a rate of 1mL/min and the 
peak of the peak was selected for assay use (Cas3) or the immediate right shoulder of the peak 
(Cascade).  Protein was concentrated in a clean 10,000 MW spin column concentrator to >10 uM 
concentration then diluted to 10 uM for Cas3 or concentrated to >5uM and diluted to 5 uM for Cascade 
in Sizing Buffer.  20-40 uL aliquots were prepared and flash frozen using liquid nitrogen and stored at -
70C for use in assays.  For indicated native gels, Cascade was not frozen but instead diluted to 5uM and 
stored at 4C for up to a month. 
Mutagenesis:  Mutant Cas3 and Cse1 proteins were produced via mutagenesis PCR amplified with lab-
purified iProof DNA Polymerase.  Each PCR reaction followed the suggested protocol from NEB (Protocol 
M0530).  PCR reactions were digested with 2uL of DpnI restriction enzyme from NEB and incubated at 
37C for ~2hrs.  DpnI digested products were then spin-column purified using a Thermo Scientific 
GENEJet PCR Purification Kit.  Products were eluted in ~30 uL of MilliQ water.  Ligation reactions were 
set up with 11.5 uL of spin-column purified products, 1.5 uL 10x T4 Ligase buffer, 1 uL Polynucleotide 
Kinase, and 1 uL T4 Ligase (all enzymes and buffers from NEB) and incubated for ~1 hr on the bench.  3 
uL of ligation reaction was transformed to lab-produced DH5-Alpha chemically competent cells or BL21 
chemically competent cells and plated on the appropriate antibiotic-resistant LB agar plates.  Single 
colonies were selected and inoculated into a 5 mL LB culture, grown at 37C for ~8-12 hrs.  Plasmid 
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purification was performed using a Thermo Scientific GENEJet Plasmid Mini-Prep Kit.  Sequencing was 
performed at the Cornell Sequencing Facility using a universal T7 reverse primer for Cas3 mutants or 
custom primers for Cse1 mutants (included in supplemental).  The plasmid was re-transformed to new 
BL21 competent cells. 
Cas3 Native Binding and Cleavage Assays:  A Cascade Substrate Loading reaction was prepared (7.5 nM 
Fluorescent-labeled substrate (Table 2.2), 40nM Cascade, 50mM HEPES pH 7.5, 150mM NaCl, 5% 
Glycerol) and incubated for 40 minutes at 58C in a thermocycler.  Cas3 was prepared in a 2560 nM stock 
and diluted to 160, 320, 640, 1280, and 2560 nM.  An equal volume of Cascade Loading Reaction 
product was mixed with the Cas3 solutions and incubated overnight at 4 C.  A 2% Agarose gel was 
prepared with TA Buffer (40mM Tris, 20mM Acetic Acid, pH corrected to ~8.2).  Running buffer was pre-
cooled and the gel was run at constant power (11W) and the gels were loaded at 4 C while current was 
flowing.  Total run-time for the gels under 11W was 3hr.  Gels were then scanned using a Typhoon 
Scanner for Cy5 or FAM tags and the better resolution between the two was used for quantification.  
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Table 2.2:  Fluorescent Substrate used for cleavage and EMSA experiments  AAG indicates the PAM, 
underlined sequence is the Cascade target site.  The average Cas3 nicking site is between the two 
nucleotides indicated in RED. 
 
 
Description Sequence 
Substrate Full Sequence taatacgactcactataggggaattgtgagcggataacaattcccctgtagaaat
aattttgtttaactttaataaggagatataccatgggcagcagccatcaccatca
tcaccacagccaggatccAAGCCAGTGATAAGTGGAATGCCATGTGGGCTGTCct
cgagtctggtaaagaaaccgctgctgcgaaatttgaacgccagcacatggactcg
tctactagcgcagcttaattaacctaggctgctgccaccgctgagcaataactag
c 
 
Substrate Forward 
Primer 
5’FAM-taatacgactcactataggg 
Substrate Reverse 
Primer 
5’Cy5-gctagttattgctcagcgg 
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For cleavage/native assays 320, 640, 1280, 2560, and 5120 nM Cas3 aliquots were prepared and diluted 
in 2x Binding Buffer (final concentrations: 50 mM HEPES pH 7.5, 150 mM NaCl, 5% Glycerol).  20 uL of 
each of the Cas3 solutions was combined with 40uL of the Cascade training solution.  From these 
solutions, two aliquots were prepared: 30uL for the cleavage reaction, 15uL for the native binding 
reaction.  The cleavage reaction received a cleavage supplement to bring the cleavage reaction to a final 
composition of 1x Binding Buffer, 20nM Cascade, 3.75 nM substrate, 2 mM ATP, 10 uM CoCl2, 10 mM 
MgCl2 and Cas3 concentrations from 80 to 1280 nM.  The 15 uL aliquots for the Native Binding assay 
were then corrected with 5 uL of 1x Binding Buffer to a final concentration of 20 nM Cascade and Cas3 
concentrations from 80 to 1280 nM.  These native binding reactions were then treated identically to the 
Native binding assays described above.  Cleavage reactions were incubated in a water bath at 58C for 40 
minutes and the samples were frozen overnight.  The next day, an equal volume of Phenol solution was 
added and the reactions were vortexed.  The aqueous phase was taken and an equal volume of 95% 
formamide solution was added, then the samples were heated to 98C for 5 minutes in a thermocycler.  
The samples were run on a pre-warmed 8% Acrylamide (19:1) 0.5x TBE urea gel for 40 minutes under 
25W of constant power.  Afterwards, the gels were allowed to cool and then were scanned for Cy5 and 
FAM fluorescent tags using a Typhoon Scanner. 
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3.1 Abstract 
Powerful genome editing tools derived from single-component CRISPR-Cas systems have revolutionized 
biomedical research. More sophisticated CRISPR systems exist, with novel enzymatic properties. Here 
we demonstrate the feasibility of using Type I CRISPR-Cas to effectively introduce a spectrum of long-
range deletions in an RNA-guided fashion in human embryonic stem cells (hESCs). Type I CRISPR-Cas 
relies on the multi-subunit ribonucleoprotein (RNP) complex Cascade to identify a DNA target, and the 
helicase-nuclease enzyme Cas3 to degrade DNA processively. When delivered as RNP, Cascade and Cas3 
introduced a variety of long-range deletions in human genome, ranging from a few hundred nucleotides 
to more than 35 kilobase-pairs, in regions upstream of the RNA-guided target site. These results 
highlight the potential utility of Type I CRISPR-Cas for the functional dissection of coding and non-coding 
regions in eukaryotic genome, and possibly in erasing large deleterious genetic elements and 
introducing long-range epigenetic modifications. 
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3.2 Introduction 
The majority of prokaryotes rely on CRISPR-Cas systems to establish adaptive immunity against foreign 
genetic elements (33, 173-177).  The diverse set of CRISPR-Cas systems rely on the basic principle of an 
RNA guide complexed with one or more proteins.  CRISPR-Cas systems are divided into two major 
classes: Class 1 systems utilize a multi-subunit effector complex to search and destroy nucleic acid 
targets, whereas Class 2 systems use a single-component effector complex (178, 179).  Each Class is 
further classified into at least three Types, based on the cas operon composition. The utilization of Cas9 
(Class 2 Type II) for RNA-guided eukaryotic genome editing revolutionized biomedical research and 
precision medicine (180-182). Guided by an engineered sgRNA, Cas9 introduces a DNA double-strand 
break (DSB) at the targeted site, which is typically repaired via the error-prone non-homologous end 
joining (NHEJ) pathway, leading to nucleotide insertion/deletions (indels) and gene disruption. 
Homology-directed repair (HDR) can also occur when a DNA template is present, leading to template-
guided gene conversion. A wide variety of Cas9-based tools have been invented for high-throughput 
genetic screening, epigenome modification, and programmable base editing (183). So far, all CRISPR-
based eukaryotic gene editing tools (Cas9, Cas12, Cas13) were harnessed from Class 2 systems. The 
more prevalent Class 1 CRISPR systems remain as untapped resources (178). 
The most widespread and diverse form of CRISPR-Cas, the Class 1 Type I system, uses a very different 
interference mechanism from that of Cas9. Rather than introducing a single DSB at the targeted site, 
type I systems shred the DNA target processively through a multi-step process. First, a multi-subunit 
RNP called Cascade (CRISPR associated complex for antiviral defense) uses a CRISPR RNA (crRNA) to 
recognize a complimentary target flanked by a 5’ protospacer adjacent motif (PAM). This results in 
stable R-loop formation and triggers a large conformational change in Cascade. The helicase-nuclease 
fusion enzyme Cas3 is then specifically recruited to the R-loop-forming Cascade, nicks the non-target 
strand (NTS) DNA, and processively degrades its upstream region (PAM-proximal side). Cas3 further 
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degrades the target strand (TS) DNA, although the detailed mechanism remains unclear. Among 
different subtypes (I-A to I-G), the best-understood are the Type I-E systems from E. coli (184-193) and 
Thermobifida fusca (Tfu) (55, 57, 83, 194, 195).  
 
3.3 Results 
In this study, we explored the feasibility of achieving RNA-guided genome editing in hESCs using Type I 
CRISPR-Cas. We chose the T. fusca type I-E system for its clearly defined mechanisms relative to other 
Type I systems and the highly active Cas3 nuclease (Figure 3.1A). However, the optimal growth 
temperature for T. fusca is 55 ˚C and R-loop formation by TfuCascade exhibits a strong temperature 
dependence (195), which presents a potential technical hurdle for its adaptation to mammalian systems.  
Although robust interference activity was previously observed from T. fusca Type I-E CRISPR at 37 ˚C in 
vivo (194), as a precaution, we screened a number of structure-guided mutations aimed at weakening 
the thermo-adaptation features in TfuCascade. We found that TfuCascade bearing a N23A mutation in 
the Cse2 subunit (195) was more specific in DNA-binding and equally efficient in R-loop formation at 
mesothermic temperature (Fig. 3.2A). More importantly, this mutant was more efficient in recruiting 
TfuCas3 for DNA nicking and degradation at 37 ˚C (Fig. 3.2B). To assay for genome editing activity (Fig. 
3.1B), we created a hESC dual reporter line (H9-DNMT3B-tdTomato/EGFP) bearing knock-ins of a 
tandem dimer tomato fluorescent protein (tdTomato) gene and a enhanced green fluorescent protein 
(EGFP) gene at the two alleles of the highly expressed DNMT3B locus (Fig. 3.1C). RNA-guided disruption 
of the EGFP allele would lead to the accumulation of cells expressing tdTomato only, and vice versa for 
tdTomato disruption. Electroporation of TfuCas3 and TfuCascade RNP was chosen as the delivery 
strategy to avoid the potential complications of expressing a multi-subunit RNP complex in hESCs. 
Nuclear localization signals (NLSs) were appended to the C-terminus of TfuCas3 and the C-terminus of 
each of the six Cas7 subunits in TfuCascade (Fig. 3.2C-D) to promote nuclear uptake.  
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Figure 3.1: Type I CRISPR-Cas can enable RNA-guided genome editing in human ES cells. (A) Schematic 
diagram of the T. fusca Type I-E CRISPR-cas locus. Black rectangles and blue diamonds represent CRISPR repeats 
and spacers; colored boxes, cas genes. (B) Procedure of the genome editing experiments in hESCs. (C) Schematic of 
the hESC dual-reporter line bearing EGFP and tdTomato at the DNMT3B locus. Protospacers for the three reporter-
targeting crRNAs are indicated in blue, and corresponding PAMs in magenta. (D-E) Flow cytometry analysis of the 
dual-reporter hESC line 4-5 days after RNP delivery. Percentages of EGFP-negative tdTomato-positive cells are 
indicated in (D), and percentages of EGPF-positive tdTomato-negative cells are indicated in (E).  Colors in D, E 
indicate density of cells detected with a certain GFP/tdTomato signal.  Cascade NT, G1, G2 and Td indicate Cascade 
with guides that do not target the genome and are thus non-targeting (NT), target GFP at Guide 1 (G1), GFP at 
Guide 2 (G2), or tdTomato (Td).
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Figure 3.2: Biochemistry on the T. fusca Type I-E CRISPR system. (A) R-loop formation behavior of WT and 
N23A mutant TfuCascade at 45 ˚C. N23A interacts with dsDNA less non-specifically. (B) In comparison with WT, 
N23A mutant TfuCascade enables more efficient DNA nicking and degradation by TfuCas3 at 37 ˚C. (C) NLS-tagged 
TfuCascade behaves similarly as the untagged version. (D) SDS-PAGE analysis of TfuCas3 and TfuCascade used in 
the genome editing experiments. TfuCascade was programmed with different guide RNAs, as referred in the text. 
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It has been observed in previous studies (and in Chapter II of this thesis) that the T. fusca Cas3 protein 
has not been very active and significant activity was only observed when supplemented with divalent 
ions, most notably cobalt, during DNA cleavage experiments (171).  This lack of activity in the absence of 
a metal supplement has also been noted in another thermophilic Cas3 from T. thermophilus (196).  And 
this trend extends to E. coli Cas3 which also needs to be supplemented with either cobalt or nickel (79, 
158).  Even so, the in-vitro activity when supplemented with divalent ions in the reaction buffer was not 
very robust.  The probable mediator of this decrease in activity is that iron is the native metal ligand for 
the reaction center of the nuclease, but when recombinantly expressed in E. coli, differences between E. 
coli and T. fusca’s cellular environment resulted in oxidation of the nuclease iron. 
Therefore, it became apparent very quickly that if TfuCas3 could be optimized out of this requirement, it 
would result in a much higher likelihood of success in gene editing experiments.  Towards this goal, I 
developed a protocol which improves the activity of Cas3 to a very high degree (~35-fold higher activity 
compared to previous) (Figure 3.3a).  The protocol involves starting the expression culture in a small 
volume of LB overnight (5mL), transferring to a larger starter culture of M9 (100mL) overnight, and then 
transferring to the expression volume (2L-8L) (see materials and methods).  Once the expression culture 
reaches OD 0.6-0.8, I lowered the temperature to 20°C and added Cobalt Chloride to a final 
concentration of 100uM.  During the expression, using M9 minimal media without a trace metal 
supplement carefully controls the presence of iron which protects the active site from being poisoned. 
Notably, in the presence of ATP, the nicking band in reactions in which the cobalt-containing Cas3 was 
used is less prominent on the non-target strand (Figure 3.3b, 3.3c).  This is an indication that processive 
activity is higher and/or that nuclease activity is stronger, since the fluorescent signal is being spread out 
over a more diverse set of non-specific cleavage products.  Increase in cleavage of the target strand also 
corresponded with the increase in non-target strand activity.  
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Figure 3.3: Improvement of Cas3 nuclease activity a) Design of the substrate used in the cleavage 
experiment of panel c.  The 5’ end of the target strand is labeled with Cy5 (red), the 5’ end of the non-target strand 
is labeled with 6FAM (blue).  b)  Cleavage assay showing increased nuclease activity of Cobalt-purified Cas3.  c)  
Quantification of uncleaved substrate in (b) in the presence of ATP expressed as a fraction of fluorescent signal 
from uncleaved substrate  
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We programmed TfuCascade with a crRNA guide (G1) against a 32-bp region in EGFP that was flanked by 
an interference-enabling PAM (5’-AAG) (Fig. 3.1C), and electroporated it together with TfuCas3 into the 
hESC dual-reporter line. A sub-population (7.3%) of EGFP-negative/tdTomato-positive cells were 
detectable by flow cytometry after 4-5 days (Fig. 3.1D). Negligible levels of EGFP-negative/Tomato-
positive cells were detected in control transfections that included a non-targeting (NT) TfuCascade and 
TfuCas3, or TfuCas3 alone (Fig. 3.1D). To further demonstrate that this novel editing platform is 
programmable, we evaluated two additional TfuCascade RNPs. Co-delivery of a TfuCascade-G2 targeting 
the opposite strand of GFP (Fig. 3.1C) together with TfuCas3 lead to the accumulation of 2.7 % EGFP-
negative/tdTomato-positive cells (Fig. 3.1D). Furthermore, electroporation of a tdTomato-targeting (Td) 
TfuCascade in conjunction with TfuCas3 resulted in a 2.7% Tomato-negative/EGFP-positive cell 
population (Fig. 3.1E). No apparent cell toxicity was noticed for any combination of Cas3 and/or Cascade 
delivery. A small fraction of cells lacking both EGFP and Tomato fluorescence were observed for each 
sample, even when no CRISPR components were delivered. This was most likely caused by spontaneous 
hESC differentiation that led to repression of DNMT3B-driven reporter gene expression. Collectively, 
these experiments suggest that type I-E CRISPR systems can induce programmable gene disruption in 
hESCs, and that both the nuclease-helicase Cas3 and a cognate Cascade are required. 
The efficiency of EGFP disruption positively correlated with TfuCascade concentration, increasing from 
3.3% to ~13.1% when the amount of TfuCascade-G1 RNP was increased from 20 to 80 pmole, with 
TfuCas3 concentration kept constant at 20 pmole (Fig. 3.4A). Similarly, increasing the amount of 
transfected TfuCascade-G2 RNP also lead to enhanced editing efficiency (Fig. 3.4B). In contrast, 
doubling, tripling or quadrupling the amount of TfuCas3 while keeping Cascade concentration constant 
did not improve editing efficiency (Fig. 3.4C). These findings suggest that the editing efficiency in hESCs 
is currently limited by the target-searching efficiency of TfuCascade rather than the DNA cleavage 
activity of TfuCas3.  
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Figure 3.4: Optimization of genome editing efficiency. (A-C) Flow cytometry analysis of dual-reporter hESC 
line 4 days after RNP delivery. Increasing amount of TfuCascade-G1 or TfuCascade-G2 was used in conjunction with 
constant TfuCas3 in (A) and (B). Increasing amount of TfuCas3 was used in conjunction with constant amount of 
TfuCascade-G1 in (C). Percentages of EGFP-negative tdTomato-positive cells are indicated. 
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Based on prior knowledge of how type I CRISPR cleaves DNA, we speculated that chromosomal deletions 
were induced upstream (i.e. PAM-proximal side) of the target site. To define these lesions, we extracted 
genomic DNA from TfuCascade-G1/Cas3 edited hESCs before and after fluorescence activated cell 
sorting (FACS), and PCR-amplified a ~5.1 kb region using two primers spanning a region 4.7 kb upstream 
and 400 bp downstream of the target site (Fig. 3.5A). The unedited cells and the TfuCascade-NT/Cas3 
treated cells served as two negative controls; both produced a single PCR band of 5.1 kb, suggesting that 
the DNMT3B-EGFP locus was intact (Fig. 3.5B, lanes 1-2). The amplicon from the unsorted total cell 
population after the TfuCascade-G1/Cas3 treatment contained a faint ladder of smaller bands in 
addition to the full-length band, indicating that a fraction of these cells harbored deletions of varying 
lengths at the DNMT3B-EGFP locus (Fig. 3.5B, lanes 3). Notably, PCR amplification from the FACS-sorted 
EGFP-negative/tdTomato-positive cells were enriched with a distribution of smaller products, ranging 
from ~5 kb to 1 kb in size (Fig. 3.5B, lane 4). Speculating that some deletions may extend beyond the 4.7 
kb detection limit, we repeated the same experiment using a different forward primer annealing further 
upstream (~8.5 kb) of the target site (Fig. 3.5A). The result revealed that the chromosomal deletions 
were indeed well-represented all the way to ~7.5 kb (Fig. 3.5B, lanes 5-8). Control PCRs amplifying a 5.5 
kb region downstream of EGFP revealed no detectable genomic deletions (Fig. 3.5B, lanes 9-12). This 
profile is in stark contrast to the eukaryotic gene editing profiles by the RNA-guided Cas9 or Cas12 
nucleases, which typically lead to small indel formation at the target site. 
  
We further attempted to map the precise boundaries of Cascade-G1/Cas3-induced lesions. In a low-
throughput approach, we topo-cloned the amplicons from FACS-sorted samples in lanes 4 and 8 of Fig. 
3B, and randomly picked fifteen clones for Sanger sequencing to identify the chromosomal junctions. 
Each clone revealed a unique chromosomal deletion profile upstream of the target site (Fig. 3.5C, Table 
3.1). These data suggest that the Type I-E CRISPR induces at least two DSBs in this region, and possibly 
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more in between. In all cases, the 5’ and 3’ regions flanking the deletions were directly re-ligated, 
presumably by the host NHEJ pathway. The 5’ lesion boundaries, which likely reflect the last DSB 
generated by Cas3 before dissociating from the DNA, are distributed across a region several kb in size, 
highlighting the heterogeneous nature of Cas3-induced deletions. An unexpected finding was that the 3’ 
boundaries of these lesions, which represent the first DSB by Cas3, did not line up precisely at the 
Cascade recognition site. Instead, they spread out stochastically within the 273 nt EGFP coding region 
upstream of the target site (Fig. 3.5C). More editing events likely started further upstream in a long 
intron preceding the EGFP coding sequence, which may not be detectable in cells enriched by FACS 
given that EGFP expression may be unaffected. This observation is difficult to rationalize based on the 
existing mechanistic model, as it suggests that Cas3 is not capable of generating a DSB during the very 
initial phase of DNA translocation. Previous single molecule biochemistry revealed that after recruitment 
by Cascade, Cas3 initially reels dsDNA towards itself repeatedly while still associated with Cascade, then 
eventually dissociates from Cascade and translocates on DNA for kilobases in distance (83); in both 
phases NTS DNA was sporadically erased, leading to the exposure of TS ssDNA (83, 197). However, DSB 
formation was not observed at the single molecule level, even though DNA were found in bulk 
experiments to be shredded into pieces, (83, 197). This discrepancy could not be rationalized in the past. 
Here our human cell genome editing experiments revealed a surprising DSB formation pattern, 
suggesting that the current understanding of the DNA degradation mechanism by Type I CRISPR 
machinery is still incomplete and can be further illuminated by human cell gene editing studies.  
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Figure 3.5: PCR and Sanger-sequencing based characterization of genomic lesions induced by Type I 
CRISPR-Cas. (A) Schematic of the EGFP reporter at DNMT3B locus and annealing sites for five PCR primers used in 
(B) and (C), and four primers used in (E) and (F). Positions relative to the EGFP translation start site (+1) are 
indicated. Recognition sites for Cascade G1 and G2 are marked by the dashed blue line. Blue arrowhead, direction 
of Cas3 translocation. (B) PCR-based genomic lesion characterization. A spectrum of chromosomal lesions was 
introduced upstream of EGFP by a EGFP-targeting Cascade-G1 and Cas3, in the sorted EGFP-negative population, 
as well as unsorted total cells. PCR primers used are indicated and their annealing sites depicted in (A). (C) 
Representative lesion locations revealed by cloning of the entire PCR in lanes 4 and 8 of (B) and Sanger sequencing. 
Black lines, deleted regions. (E) PCR-based lesion analysis. A collection of chromosomal deletions was induced 
downstream of EGFP by a EGFP-targeting Cascade-G2 and Cas3, in the sorted hESCs. PCR primers used are 
indicated and their annealing sites depicted in (D). (F). Representative lesion locations revealed by cloning and 
sanger sequencing of the PCR in lane 3 of (E). Black lines, deleted regions. 
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Table 3.1: Summary of Lesion Boundaries.  5’ and 3’ boundaries of lesions caused by GFP-targeting 
guides G1 or G2, identified via low throughput TOPO cloning and sequencing of GFP regions from FACS 
sorted GFP- cells. Positions listed are relative to the start (+1) of EGFP ORF. 
 
Cascade-G1/Cas3 induced lesions, shown in Fig. 3.5C 
No # 5’ end 3’ end No # 5’ end 3’ end 
1 -2377 134 9 -7800 178 
2 -4200 155 10 -7691 270 
3 -2048 11 11 -7236 54 
4 -3702 208 12 -1822 116 
5 -2593 98 13 -7631 93 
6 -2972 103 14 -7923 156 
7 -3005 88 15 -7069 86 
8 -2621 2    
Cascade-G2/Cas3 induced lesions, shown in Fig. 3.5F 
1 445 4478 5 635 4747 
2 508 5432 6 648 3486 
3 509 4429 7 802 5414 
4 517 5046    
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We further used a tagmentation- and next-generation sequencing (NGS)- based method to define Type I 
CRISPR-induced genome lesions more comprehensively. The genomic DNA of FACS-sorted, Cascade 
G1/Cas3 edited hESCs from the experiment in Fig. 1D was treated with adaptor-loaded Tn5 transposase, 
which randomly fragments DNA and attaches a single type of adaptor onto the fragmented ends. We 
then did a multi-step PCR using nested EGFP primers and a primer specific for the Tn5 adaptor to enrich 
for sequences spanning the junctions (Fig. 3.6A). The resulting NGS library was sequenced on an Illumina 
MiSeq, and 275 X 25 bp paired-end reads were analyzed to determine the extent of the corresponding 
deletions, as described in Methods. We detected lesion junctions in 8.9% of a total of 550,000 reads for 
the FACS-sorted sample, but in less than 0.01% of reads from the un-transfected control hESCs. Analysis 
of the lesion endpoints revealed that, consistent with Sanger sequencing results, the vast majority of 3’ 
endpoints occur within a ~450 bp window upstream of the EGFP gene. The locations of the 5’ 
boundaries are far more random and can occur tens of kilobases upstream (Figs. 3.6B and 3.6C). The 
majority of the Type I-E-induced chromosomal deletion sizes are distributed within a 10 kb range, 
however, a portion of deletions exists even up to 50 kb (Fig. 3.6C). 
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Figure 3.6: Tn5 and deep-sequencing based characterization of Type I CRISPR-induced genome 
lesions. (A) Schematics of Tn5 tagmentation-based NGS library construction. (B)-(C) Scatter plot for lesion-
containing reads, showing the 5’ (X-axis) and 3’ (Y-axis) end points of chromosomal deletions, relative to the EGFP 
translation start site (+1) at the DNMT3B region. Dashed dark and light green lines, the start and end of the EGFP 
ORF; dashed blue line, recognition site for Cascade-G1. (C) is a zoom-in view of the same plot in (B). (D) Histogram 
showing the distribution of lesion lengths observed. Dark blue lines, precise locations of each observed lesion.  
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In its prokaryotic environment, Type I CRISPR interference typically eradicates targeted foreign DNA 
completely, or causes cell death if it were accidentally programmed against self-genome. The large 
chromosome size and strong intrinsic NHEJ activity attributable to human cells enabled us to explore the 
T. fusca type I-E CRISPR-Cas machinery at a much greater depth than previously described. Although the 
stochastic nature in the onset of genome deletion and the wide-range of deletion sizes was somewhat 
unexpected, this nonetheless opens new avenues for further mechanistic investigations. Moreover, an 
encouraging 13% genome editing efficiency could be achieved ex vivo in hESCs without the use of 
selectable markers.  Also notable is that these results establish a lower bound on editing efficiency, not 
an upper bound, as disruption of the reporter will only be accomplished if the start of the lesion occurs 
in the first 270 bp for G1.  Many more lesions may exist which were not detected by the reporter 
because the first double strand break of the lesion occurs outside of this range.  The efficiency may be 
improved further by switching to a plasmid or mRNA-based delivery method to increase effector 
concentration and perdurance. Higher efficiencies may also be achieved by further improving 
TfuCascade’s activity at 37 ˚C through directed evolution, or screening additional Type I CRISPR-Cas to 
identify more active gene-editors. 
Various Cas9-based genetic screening methods now allow high-throughput functional genomics 
interrogation, which typically rely on a tiling library of sgRNA or sgRNA pairs (183, 198-201). The ability 
of the Type I system to introduce a spectrum of long-range deletions from a single target site would 
enable more effective and cost-effective non-coding CRISPR screens, because far fewer RNA guides are 
needed and each guide leads to a library of deletion mutants. Conceivably, precise removal of large 
disease-related genetic elements can also be achieved with a pair of Cascade/crRNAs spanning the 
pathological region. Moreover, Type I CRISPR can potentially be adopted for long-range epigenetic 
modifications, by accompanying Cascade with two different versions of Cas3, a small portion of helicase-
dead Cas3 to initiate target DNA nicking, enabling the loading and translocation of nuclease-dead Cas3 
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fused with an epigenetic writer to introduce long-range epigenetic modifications. These Type-I CRISPR-
based applications would greatly expand the genome engineering toolkit.  
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3.6 Materials and methods 
Information on plasmid expression plasmids and GFP/tdTomato plasmids is shown in Table 3.2  
Information on oligonucleotides used to generate those plasmids and for PCR analysis are shown in 
Table 3.3. 
Expression and purification of TfuCas3 and TfuCascade 
T. fusca Cascade and Cas3 was purified as described previously (57), with minor modifications. 
TfuCascade was recombinantly expressed in E. coli BL21cells in LB media using a three plasmid 
coexpression system. Cse1 is encoded in one plasmid with an N-terminal 6xHis-TwinStrep-SUMO tag 
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(pET19b). The rest of the Cascade components (Cse2, Cas7, Cas5e, and Cas6e) were encoded 
polycistronically in another vector (pCDF-Duet1), with a C-terminal NLS tag on Cas7. The crRNA was 
expressed from a synthetic CRISPR array containing three repeats and two spacers in ORF1 of pRSF-
Duet1. Cells were grown at 37°C until the OD600 is between 0.6 and 1.0. Protein and RNA expression 
were induced by adding IPTG to a final concentration of 0.5 mM, and allowing the cell to grow overnight 
at 22˚C. 12 liters of cells were harvested and lysed by sonication in Lysis Buffer containing 30 mM HEPES 
pH 7.5 and 500 mM NaCl. The supernatant after centrifugation was loaded onto ~5 mL of StrepTactin 
resin and 2 mg per L of cells Avidin was supplemented to prevent cellular biotin from binding to the 
column. The column was washed with 3x15 ml of lysis buffer, and the protein was eluted with 10 ml of 
lysis buffer supplemented with 5 mM Desthiobiotin. After cleaving the TwinStrep-SUMO tag with SUMO 
protease overnight at 4 ˚C, TfuCascade was concentrated and buffer-exchanged to a buffer containing 
30 mM HEPES pH 7.5 and 200 mM NaCl, and further purified on MonoQ.  The final RNP was buffer-
exchanged to 30 mM HEPES pH8.0 and 150 mM NaCl, sterilized with a syringe filter, concentrated to >20 
M, and flash-frozen for -80°C storage.  To account for the nucleic acid component of TfuCascade, 
nanodrop UV 260/280 measurements were taken alongside a Bradford Assay standard curve.  A 
conversion ratio was determined to more accurately estimate the concentration of the protein 
components. 
TfuCas3 was expressed from M9 minimal media with an N-terminal TwinStrep-PreScission tag and a C-
terminal 2xHA-NLS tag from a pET52b plasmid.  A 5 ml starting culture was grown from LB media 
overnight at 37°C, propagated to a 100 mL M9 culture overnight at 37°C, then used to inoculate 3x2 L of 
M9 media. The trace metal supplement was left out of the standard M9 media to prevent Fe2+ 
incorporation into the Cas3 active site. 100 M final concentration of cobalt chloride was added to the 
cell culture 30 minutes prior to IPTG induction, when the OD600 reached 0.6. Protein expression was 
induced by 1 mM IPTG overnight at 20°C. The cells were harvested, resuspended in lysis buffer (30 mM 
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HEPES pH 7.5 and 500 mM NaCl), lysed by sonication, and purified with a Strep-Tactin column similar to 
TfuCascade purification.  The eluted protein was treated with PreScission protease overnight at 4°C to 
remove the TwinStrep tag.  Cas3 was further purified over a HiLoad Superdex 200 size-exclusion column 
(SEC) equilibrated at 30 mM HEPES 7.5 and 150 mM NaCl. The main peak fractions were pooled and 
concentrated, flash-frozen in liquid nitrogen, and stored at -80°C until needed.  
75 
 
Table 3.2: Plasmids used in this study. 
Plasmid names (Backbone/Insert) Source 
pET19b/TwinStrep-SUMO-wt CasA Xiao et al., 2017 
pCDF-Duet1/N23A CasB, CasC-NLS, CasD, CasE This paper 
pCDF-Duet1/N23A CasB, CasC-NLS, rbs-CasD, CasE This paper 
pRSF/crRNA expression, streamlined This paper 
pRSF/crRNA-G-1 expression, streamlined This paper 
pRSF/crRNA-G-2 expression, streamlined This paper 
pRSF/crRNA-G-Td expression, streamlined This paper 
pRSF/crRNA-G-NT expression Xiao et al. 2017 
pET28b/Cas3-2xHA-NLS This paper 
hES-2A-DNMT3B-EGFP This paper 
hES-2A-DNMT3B-tdTomato This paper 
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Cell Culture 
Human ESCs were cultured in E8 medium on matrigel (Corning) coated tissue culture plates at 37˚C and 
5% CO2 in a humidified incubator, with daily media change. Cells were split every 4-5 days with 0.5 mM 
EDTA in 1x PBS. 
Construction of hESC Dual-Reporter Line and DNMT3b targeting plasmids 
Cells for transfection were harvested 2 days post passaging using TrypLE (Life Technologies) and 
resuspsended in OptiMem (Life Technologies) at a final concentration of 5 x 106 cells/mL. 500 μl of the 
cell suspension was added to a 0.4 cm cuvette containing 30 μg of the linearized DNMT3B-EGFP vector. 
Cells were electroporated using condition 320V, 200 μF, then plated on a 10 cm matrigel-coated dish in 
E8 media supplemented with 10 μM Y-27632 (Cayman Chemical). 0.5 μg/mL puromycin was added to 
the medium 3 days post-transfection and drug-resistant colonies exhibiting uniform EGFP expression 
were identified by fluorescent microscopy. A single EGFP+ clone was expanded and the puromycin 
selection cassette removed following electroporation of CRE recombinase mRNA. A subsequent round of 
targeting was performed as described above using the DNMT3B-tdTomato vector. Individual colonies 
expressing both tdTomato and EGFP reporters were identified, isolated and expanded. Successful 
biallelic targeting of the endogenous DNMT3B was confirmed by genomic DNA PCR using primers 
flanking the DNMT3B start codon. 
To create DNMT3B targeting constructs (hES-2A-DNMT3B-EGFP and hES-2A-DNMT3B-tdTomato), a BAC 
clone (CTD- 2608L15) containing the complete DNMT3B coding region was obtained from the CalTech 
Human BAC Library (Life Technologies). Red-ET recombination was used to insert a DNA cassette 
encoding a tdTomato or EGFP reporter gene adjacent to a loxP-flanked PGK promoter driven puromycin 
resistance gene at the DNMT3B start codon in exon 2 of the DNMT3B gene. The ~40-kb SbfI fragment 
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containing the modified DNMT3B locus was then subcloned into the copy number inducible BAC vector, 
hES-2A. Prior to transfection these DNMT3B gene targeting vectors were linearized by SwaI. 
RNP Electroporation of hESCs 
The H9-DNMT3B-tdTomato/EGFP cells were electroporated using the Neon Transfection system 
(ThermoFisher) according to the manufacturer’s instructions. Briefly, reporter cells were individualized 
with Accutase (ThermoFisher), washed once with DMEM/F12 (ThermoFisher) and resuspended in Neon 
buffer R to a concentration of 2x106 cells/mL. 20-100 pmoles of NLS-TfuCascade and 20-60 pmoles of 
NLS-TfuCas3 were mixed with approximately 105 cells in buffer R in a 10 μL a total volume. This mixture 
was then electroporated with a 10 μL Neon tip (1100V, 20ms, 2 pulses) and plated in 24-well matrigel-
coated plates containing 500 μL of E8 supplemented with 10μM Y-27632. The media was changed to 
regular E8 24 hours after electroporation. Cells were cultured in E8 with daily media change until 
analysis. 
Flow Cytometry 
Cells were individualized with Accutase 4-5 days after electroporation and resuspended in DMEM/F12 
media immediately before experiments. For analysis, individualized cells were analyzed on an LSR 
Fortessa (BD) using 488nm laser for EGFP and 561nm laser for tdTomato. Data analysis was performed 
using FlowJo® v10.4.1. For FACS sorting, individualized cells were put on Synergy cell sorter (Sony) and 
GFP negative cells were sorted directly into a well of a 24-well plate coated with matrigel and filled with 
1.5ml E8 media supplemented with 10 μM Y-27632 and 25 μg/mL recombinant human albumin (Sigma). 
Sorted cells were then cultured in tissue culture incubator with 5% CO2 at 37˚C. Media was changed to 
regular E8 one day after sorting and daily media change with E8 was carried out thereafter, for 7-10 
days. 
Lesion Analysis by PCR 
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Genomic DNAs of hESCs were isolated using Gentra Puregene Cell Kit (Qiagen) per manufacturer 
protocol. PCRs in Fig. 3B were done using Q5 DNA Polymerase (NEB) with primer pair OYZ 438+478, OYZ 
440+478 and HZG81+OYZ462, respectively. PCR products were resolved on 1% agarose gel stained by 
SYBR Safe (Invitrogen) and visualized with Chemidoc MP imager (Biorad). To characterize lesions shown 
in Fig. 3C, 40 μL of the lesion PCR reaction done for the sorted hECSc was purified using QIAquick PCR 
Purification Kit (Qiagen), and cloned into PCR-BluntII-TOPO vector (Invitrogen). Colony PCRs with M13 
forward and reverse primers were carried out from the resulting colonies and large amplicons were 
Sanger sequenced. PCRs in Fig. 3E were perform with primer pair HZG707+OYZ462 and OYZ438+826. 
Lesions shown in Fig. 3F were characterized with TOPO cloning and Sanger sequencing. 
Tn5 Tagmentation-based NGS Library Construction 
Tn5 transposase was purified and loaded with one pre-annealed oligo pair ME-A/ME-rev as previously 
described (202). Tagmentation was performed in 10 mM Tris pH8.5, 5 mM MgCl2, 8% PEG8000 using 
60ng of genomic DNA and 700 ng of loaded Tn5, in a 20 µL total volume. After a 7 min incubation at 
55˚C, tagmentation reactions were purified using QIAquick PCR Purification Kit. For NGS library 
construction, 1st step PCR amplification was carried out using Q5 DNA Polymerase for 15 cycles with 
oligos OYZ510+478, and then treated with Exonuclease I (NEB) to digest excess primers. 2nd step of 
nested-PCR was amplified for another 15 cycles with OYZ510+511. After Exonuclease I treatment, the 3rd 
step PCR was amplified for 10 cycles with OYZ510 and index primers. The final NGS libraries were 
purified using AMPure XP beads (Beckman Coulter, 1:1 ratio), eluted in 10 mM Tris pH 8.5, pooled 
together and sequenced on Illumina MiSeq with a Nano kit for 275 x 25 bp paired-end reads. 
NGS Data Analysis 
MiSeq sequencing reads were quality trimmed using Trimmomatic v0.33 (203) with filter settings 
"TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:10", and then aligned to a defined window of the genome 
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spanning ~130 kb, which covered the entire DNMT3b locus with EGFP sequence inserted. Alignment was 
performed using bowtie2 v.2.1.0 (204) using default settings in local mode, allowing up to two 
alignments per read, and requiring stranded alignment of the forward read (originating from the Tn5 
insertion end) with the forward direction of the reference sequence.  
Subsequently, we filtered the alignments to identify potential chromosomal junction events as follows: a 
single read with two alignments was considered a junction if one alignment had cigar string wMxS and 
the other alignment had cigar string ySzM (corresponding to a case where one alignment matched the 
first portion of the read, and the other matched the second portion of the read); we further required 
that the magnitude of the difference between w and y be no greater than 10. Junctions were then 
assumed to occur between the position in the reference sequence y bp to the right of the leftmost end 
of the left alignment, and the position at which the unclipped portion of the right alignment 
begins. Count tables were obtained indicating the junctions corresponding to each lesion event. N.b. 
most lesions were observed repeatedly across many reads.  
QUANTIFICATION AND STATISTICAL ANALYSIS  
All genome editing and in vitro experiments were repeated three times, representative FACS plots and 
gel images were shown.   
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Table 3.3. Oligonucleotides used in this study. 
No. Oligo Name Sequence, 5’-3’ Purpose 
For Cascade, Cas3 expression and purification. 
0117 CasC NLS 2 Fwd GGCAAGCTTCCCAAGAAGAAGAGGAAGGTGGAGGGGGAGCGGGAG
TGAGTG 
pCDF-Duet1 / 
wt CasB, CasC-
NLS, CasD, CasE 
0118 CasC GSLink 2 Rev ACCTGAACCGCTACCGAAGGCTGCCGCGACCATGG 
0136 CasD RBS Fwd TTTAAGAAGGAGATATACATATGAGTGGCTTCCTGCTGCGGCTA pCDF-Duet1 / 
wt CasB, CasC-
NLS, rbs-CasD, 
CasE 
0137 CasD RBS Rev attaaagttaaacaaaaTTATTCCCGCTCCCCCTCCACC 
0134 pRSF conversion for 
crRNA Fwd 
tcatcgaatttttgcagcag pRSF/crRNA 
expression, 
streamlined 
0127 pRSF conversion for 
crRNA Rev 
accatggcctatagtgagtcgtattaatttcctaatgc 
0113 Cas3 CTD+2XHA-NLS 
(gBlock) 
cacgtgctcgcgacccggttcggtgccggttcagtccgggtgttgtgctactacgtggacacg
gcggggaaccgctggcttgaccctgaatgcacggtcgagtttcctgaacagggcacggggc
gagagggccggttcaccatggcagactgccgcgacctggtggcccgcacgatcccggtgcg
tatgggtccctgggcgagtcaactcaccgaggacaaccatcctcctgaggcatggcgggag
tcgttctaccttcgcgacctggttcttatacctcaacgtgtgacagacgagggcgcggtgctc
cccactgaaaccggtggacgagagtggttgcttgatccctgtaaggggctgatctttGGAT
CCGTTggtTACCCATACGATGTTCCTGACTATGCGGGCTATCCCTATGA
CGTCCCGGACTATGCAGGATCCTATCCAGAATTCcccaagaagaagaggaa
ggtgtAactcgag 
pET28b/Cas3-
2xHA-NLS 
 GFP crRNA-G1 
Synthesis 
gaattcGAGCCCCACGCACGTGGGGATGGACCGGCTACGTCCAGGAGC
GCACCATCTTCTTCAAGGTGAGCCCCACGCACGTGGGGATGGACCGG
pRSF/crRNA-G-1 
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CTACGTCCAGGAGCGCACCATCTTCTTCAAGGTGAGCCCCACGCACGT
GGGGATGGTGACaagctt 
 GFP crRNA-G2 
Synthesis 
aagcttGAGCCCCACGCACGTGGGGATGGACCGTCGATGCCCTTCAGC
TCGATGCGGTTCACCAGGTGAGCCCCACGCACGTGGGGATGGACCGT
CGATGCCCTTCAGCTCGATGCGGTTCACCAGGTGAGCCCCACGCACG
TGGGGATGGTGACgcggccgc 
pRSF/crRNA-G-2 
 crRNA-NT Synthesis gaattcTAATACGACTCACTATAGGGAGCCCCACGCACGTGGGGATGG
ACCGCCAGTGATAAGTGGAATGCCATGTGGGCTGTCGTGAGCCCCAC
GCACGTGGGGATGGACCGCCAGTGATAAGTGGAATGCCATGTGGGC
TGTCGTGAGCCCCACGCACGTGGGGATGGACCGCCAGTGATAAGTG
GAATGCCATGTGGGCTGTCGTGAGCCCCACGCACGTGGGGATGGAC
CGCCAGTGATAAGTGGAATGCCATGTGGGCTGTCGTGAGCCCCACGC
ACGTGGGGATGGACCGCCAGTGATAAGTGGAATGCCATGTGGGCTG
TCGTGAGCCCCACGCACGTGGGGATGGACCGCTAGCATAACCCCTTG
GGGCCTCTAAACGGGTCTTGAGGGGTTTTTTggatcc 
pRSF/crRNA-NT 
 tdTomato crRNA 
synthesis 
ATATCATAGTACAATAGGATCCGAGCCCCACGCACGTGGGGATGGAC
CGctggacatcacctcccacaacgaggactacacGTGAGCCCCACGCACGTGGG
GATGGACCGGAATTCAGTCGTAGTTTCGCGCATCATGGCCATA 
pRSF/crRNA-G-
Td 
For PCR-based lesion analysis 
OYZ438 DNMT3b-F-4.4k GATGGGGTGGGGGTTAAAGG PCR, Fig. 3B 
OYZ440 DNMT3b-F-8.2k AGTACTGCACTCTTTGCCCC 
OYZ478 EGFP-Rev acgaactccagcaggacc PCR, Fig. 3B; 
NGS library  
HZG81 DNMT3b-after EGFP-
Fwd (1.0k) 
aagggagacaccaggcatc PCR, Fig. 3B 
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HZG531 DNMT3b-exon3 Rev gagagtcgcgagcttgatct 
oYZ826 EGFP-62-81-Rev CTTGTGGCCGTTTACGTCGC PCR, Fig. 3E 
HZG707 EGFP-fwd gtgagcaagggcgaggag 
oYZ462 DNMT3b-R-6.5k GGCCAATTACTGGGTTCAGG 
For Tagmentation and NGS library preparation 
OYZ507 Tn5-ME-rev /5phos/CTGTCTCTTATACACATCT Tn5 loading 
OYZ508 Tn5-ME-A TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
OYZ510 Nextera P5  AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTC NGS library prep 
OYZ511 EGFP-302-Illumina GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTggtcttgtagttgccgtcg
t 
N/A Index 1 CAAGCAGAAGACGGCATACGAGATGAAAGACCGTGACTGGAGTTCA
GACGTGTGCT 
N/A Index 2 CAAGCAGAAGACGGCATACGAGATATGGGCACGTGACTGGAGTTCA
GACGTGTGCT 
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CHAPTER IV – SPECULATION AND CAS3 DIMERIZATION 
4.1 Type I Genome Editing Future Directions 
Chapter III of this thesis describes a novel genome editing platform based on the Type I-E CRISPR 
system.  Other Type I-E systems exist, many of which have evolved at a temperature compatible with 
mammalian genome editing.  Screening of other Type I-E systems might reveal a system which is as easy 
to work with as T. fusca, but with a more effective R-loop behavior at editing temperatures.  
Alternatively, other Type I systems exist which contain fewer unique subunit proteins, such as the Type 
I-C system of bacteria such as Bacillus halodurans (59).  These might be more effective in a plasmid 
delivery system due to the fact that the overall coding sequence is shorter. 
The wild-type T. fusca Cascade complex should also be tested in genome editing.  The trade-off 
observed in EMSA results might not represent the optimal situation.  Despite Wild-Type Cascade having 
a higher affinity for non-specific interactions, the mutation of N23A might come with other costs.  Since 
the limiting factor appears to be target binding, evidenced by the fact that Cascade concentration 
manipulation alters editing efficiency much more than Cas3 concentration manipulation, it would be 
prudent to more thoroughly screen other mutations as well as to test the Wild-Type in genome editing. 
4.2 Acquisition Speculation 
Spacer biogenesis remains one of the largest unanswered questions in the field of CRISPR biology.  Both 
for naïve and primed acquisition, the precise mechanism that provides the substrates for Cas1/Cas2 to 
integrate spacers into the genome are not well understood.  There is, however, work that has 
characterized what Cas1/Cas2 spacer substrates presumably look like in-vivo.  These substrates have 
been shown to likely possess at least one forked end in structures of Cas1/Cas2 bound to substrate DNA 
solved in our lab and by others (23, 205).  Single-molecule work in our lab has also shown that 
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processing can occur after the Cas1/Cas2 binding event in the presence of host exonucleases 
(unpublished).  This means that the forked end can be inserted to the CRISPR array and the other side 
can be processed afterwards.  This can represent an additional mechanism for selecting the orientation 
of spacer insertion in the CRISPR leader-repeat region, since the same work has shown that a substrate 
with two forked ends seems to insert bi-directionally.  The sequence of events in this model would be 
that Cas1/Cas2 binds a single-end forked DNA substrate that has been produced in an undefined process 
which ensures a PAM site at the forked end.  Then, integration at the leader side of the CRISPR locus is 
catalyzed by Cas1/Cas2.  Next, host exonucleases chew the un-integrated side of the spacer, stopping 
where Cas1/Cas2 protects the substrate.  Finally, spacer-side integration follows.  But this model still 
cannot resolve the resulting post-integration structure.  There are several hypotheses that involve 
different sets of repair machinery – since the CRISPR locus is constantly transcribed, a plausible theory is 
that transcription-mediated repair is involved in the resolution of this integration intermediary. 
It has been shown that in the Type II system, the Cas9 protein is required for PAM specificity in 
acquisition (94).  Further, when the PAM specificity of Cas9 is changed by substituting a closely related 
orthologue, it results in a change in acquisition specificity for targets adjacent to the substituted Cas9’s 
PAM preference.  This shows that PAM recognition for spacer acquisition relies on the interference 
module in the Type II system.  I believe this strongly hints towards a role for Cascade or Cas3 in spacer 
acquisition in the Type I system generally, and in selection of PAM-containing sequences specifically. 
4.3 Dimerization 
The mechanism by which Cas3 induces the double strand breaks observed in editing experiments is 
currently not well understood.  Even though cleavage has been observed on both strands of DNA in 
some experiments, others observe obligate single-stranded activity (80, 82, 158).  What causes this 
discrepancy?  One possible explanation is that Cas3 biochemistry involves multiple modes of activity.  
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One mode would be the well-characterized reeling behavior observed in single-molecule DNA curtain 
experiments (81-83).  In these setups, double strand breaks have not typically been reported in the 
literature.  In the appendix of this thesis, the first description of Cas3-mediated double strand breaks 
observed via DNA curtain is reported.  However, it is still possible that double strand breaks are caused 
in multiple ways both by dimerization and by a single Cas3, with the roadblock-dependent mechanism 
relying on either tension caused by Cas3’s helicase activity to induce the break or by Cas3’s nuclease 
domain having a rare interaction with the opposite strand of DNA.  Further, the experimental design is 
unable to distinguish between Cas3 dimerization and double strand breaks caused by a single Cas3, as 
the Cas3 used in these experiments is not fluorescently labeled.  The description of the double strand 
break and Cas3 roadblock experiments was not intended to rule out the possibility that the observations 
may have been made when excess Cas3 present in solution, allowing for dimerization to occur (see 
Materials and Methods of Appendix).  This conclusion is supported by the fact that double strand breaks 
were still observed in the absence of a roadblock to Cas3 translocation and the break sites were spread 
out over most of the substrate (Figure AI.5c). 
Further evidence for the existence of a Cas3 dimer is that it has already been observed.  When the T. 
fusca Cas3 crystal structure was originally solved, the unit cell contained four Cas3 monomers arranged 
as two dimers (171).  The arrangement of the individual dimers was head-to-tail, with the nuclease of 
one monomer next to the helicase of the other.  The interface between the two Cas3s which comprised 
the dimer could be interpreted as more extensive than would be expected from a biologically irrelevant 
crystal packing interface (Figure 4.1a).  With the more recent information from the high-resolution Cryo-
EM structure, the interface surfaces can be assigned as the same ones responsible for Cascade-Cas3 
interaction (57).  If the Cas3 dimer observed in the Huo et al. structure is biologically relevant, then it 
can safely be concluded that the Cas3 dimer activity is mutually exclusive to the Cascade-Cas3 activity 
(194). 
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Cas3’s combination nuclease-helicase behavior has been compared with RecBCD (85).  Both are 
helicase-nuclease fusions, but RecBCD has bi-directional helicase behavior (97).  RecBCD acts as a 
component in the innate bacterial immune system with the purpose of degrading exposed DNA 
processively.  However, RecBCD has another function as a detector of Chi sites and an initiator of 
recombination (97).  Cas3 as a monomer has only 3’-5’ helicase activity, however if it were present in a 
dimer, it is possible that it could travel bi-directionally.  Further parallels between RecBCD and Cas3 may 
exist in the detection of specific motifs in the substrate DNA – PAMs for Cas3 instead of RecBCD’s Chi 
sites.  This would result in a natural precursor for spacer biogenesis in CRISPR adaptation. 
Towards this end, I have begun work to test the hypothesis that the Cas3 dimer observed in the crystal 
structure might be biologically relevant.  A framework for studying Cas3 dimerization plausibly involves 
observing the transition of Cas3 from Cascade-bound DNA reeling activity to Cascade independent 
translocation.  This suggestion is strengthened by the fact that in hESC cells, Cas3-induced double strand 
breaks occur predominantly distal from the target site and only occur in the direction that Cas3 is 
expected to move, suggesting that Cas3’s helicase must be active for some time before DSB’s are 
induced (Chapter III).  This observation, combined with the observation that Cas3 has two modes of 
activity (Cascade-bound reeling vs. Cascade-independent translocation), naturally leads to the 
hypothesis that this regional transition relative to the Cascade target site from DSB-prohibitive to DSB-
permissive might coincide with a transition in Cas3’s behavior. 
Structural investigation of the question is aided by the fact that we already possess a putative structure 
of the complex at high resolution, allowing the identification of residues involved in the dimerization 
surface.  However, complicating the problem is the fact that the interface shares many contacts with the 
Cascade-Cas3 interface.  This makes functional assessment of dimerization more difficult.  Cas3 activity 
independent of Cascade has been difficult to observe, and since Cas3 alone has very little or no activity 
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on double-stranded DNA, functional studies of Cas3 dimerization interface perturbation would likely 
have to occur at sites which are independent of the Cascade-Cas3 interaction surface. 
I decided to test the Cas3 dimerization interface through mutational analysis anyway, just in case the 
Cascade-Cas3 interface could be separated from the Cas3 dimerization interface.  I generated several 
mutants at positions S171R, L794E, and A790E.  When Wild-Type Cas3 is subjected to Size Exclusion 
Chromatography, a small but reproducible dimer peak has been observed (Figure 4.1b).  When these 
Dimer interface mutants were purified over SEC, some showed a decreased or absent dimer peak.  This 
suggests that perturbation of the putative interface is having some effect, though specific conclusions 
cannot be drawn from this data alone.  When these mutants were tested in a Cascade-mediated 
substrate cleavage assay, unambiguous interpretation of the results were difficult (Figure 4.2).  The 
S171R mutant appeared to have activity comparable to Wild-Type on both the target and non-target 
strands of the substrate.  A790R, however, showed an overall decrease in substrate cleavage, but 
interestingly an increased bias towards generating nicks on the Target strand at the 3’ end.  
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a) 
 
b) 
 
 
Figure 4.1. Cas3 dimerization structure and initial mutational analysis a) 1. Cas3 Dimer Crystal Structure.  
The Cas3 dimer interface is highlighted in red on the purple sub-unit. 2. Cartoon representation of the dimer.  3. 
Cascade/Cas3 interface cartoon. b)  Cas3 dimer mutants SEC profiles.  WT Cas3 exhibits a clear dimer shoulder 
while dimer mutants exhibit a decreased or non-existent dimer fraction.  
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a) 
  
 
b) 
 
c) 
 
Figure 4.2 Cas3 dimer mutants activity assay a) Fluorescent substrate used in activity assay showing in b 
and c.  b) Activity assay showing the relative nuclease activity of wildtype Cas3, S171R, A790R, and 
L794R acting on the target strand of the fluorescent substrate in a. c) The same gel from b, scanned for 
activity on the non-target strand. *NTS-Nick Site | †NTS-R-loop Start | ‡Nick-50bp Cas3 concentrations are 
50 nM, 200 nM, 800 nM.  
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It became apparent that bulk biochemical investigation of the dimerization hypothesis would prove to 
be exceptionally difficult since controlling the formation of the dimer would be difficult in reaction 
conditions where Cas3 would always necessarily be provided in excess.  Performing the experiment in a 
flow-cell allows the substrate to be bound to the surface and proteins and reagents can be flowed in 
sequentially in a controlled manner (Figure 4.3a).  This allows for Cascade bound to substrate on the 
surface of the flow cell to recruit a single Cas3 in the absence of ATP.  Excess Cas3 can be washed away, 
leaving the Cascade-bound Cas3 stably associated.  Addition of ATP initiates Cas3 translocation, and 
subsequent addition of Cas3 theoretically allows for more control over the formation of the putative 
Cas3 dimer.  The Cas3 dimer model also lends itself to single-molecule FRET (smFRET) investigation.  If 
two populations of Cas3 labeled with a FRET-compatible fluorophore pair were used in smFRET 
experiments, dimerization would have an unmistakable and clear signal that proves the formation of the 
dimer on substrate DNA (Figure 4.3b). 
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a) 
 
b)  
 
c) 
 
Figure 4.3: Framework for testing Cas3 Dimerization by smFRET. a) Schematic of smFRET flow cell.  b) 
Design of ideal smFRET Cas3 dimerization experiment.  The first fluorophore-labeled Cas3 is loaded to Cascade and 
synchronized at an impassible roadblock by providing ATP.  Then, a second population of fluorophore-labeled Cas3 
is flowed in, FRET signal is observed and a loss of the third fluorophore confirms the DSB. c) FRET trace of Cas3 
activity in the flow-cell, showing Cas3 translocation up to and past the C6amino-dT modified with NHS-Cy3.   
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As initial tests of the T. fusca Cascade/Cas3 system in single-molecule experiments, I prepared a 
substrate that contains a C6-amino-dT modification which was labeled with NHS-Cy3.  This substrate 
also contained a Cascade target site such that Cas3, after being recruited to the substrate by Cascade, 
would track along the strand and approach the fluorophore on the same strand.  In previous helicase 
characterization studies, C6-amino-dT-fluorophore has had differing conclusions on whether or not the 
modification was capable of stalling various helicases.  When Cy5-labeled Cas3 approached the 
fluorophore, smFRET traces showed that it is capable of overcoming, bypassing, or dissociating from the 
obstacle (Figure 4.3c).  Some other traces showed that Cas3 might pause in some fraction of these 
events, but not for very long.  These experiments served as an encouraging sign that the system works 
well and in a predictable manner, but would not ultimately help in the determination of whether or not 
dimerization occurs. 
Towards this end, a new substrate with an E. coli Ter site near the biotin-labeled terminus was designed 
with a C6-amino-dT modification.  The Ter site is a strong DNA roadblock used during E. coli genomic 
replication and is bound by the protein Tus.  The Ter site is a direction-dependent roadblock to 
replication such that it only prevents translocation along DNA from a single side, and so the roadblock 
site was designed such that the non-permissive orientation was presented to Cas3 translocation.  This 
experimental setup with Tus as a roadblock to Cas3 translocation remains to be tested. 
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APPENDIX I 
APPENDIX I CREDITS: 
This work constitutes a collaboration with the Finkelstein lab at University of Texas and was published in 
Cell in 2018.  As described in the author contributions section Maxwell Brown, Kaylee Dillard, Logan 
Myler, Yibei Xiao, Ailong Ke, and Ilya Finkelstein conceived of the study.  The DNA curtain experiments 
were performed by Maxwell Brown, Kaylee Dillard, and Logan R. Myler.  Yibei Xiao and I purified protein 
used in the study, with my primary contribution being the provision of Cobalt-purified Cas3, which 
increased the rate that Cas3 activity was observed, improving the quality of the study.  I also performed 
the in-vivo experiments to assay mutant Cascade complexes.  Erik Hernandez and Samuel Dahlhauser 
provided fluorescent peptides.  Yoori Kim provided software used for data analysis.  The manuscript was 
written by Maxwell Brown, Kaylee Dillard, and Ilya Finkelstein. 
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AI.1 Abstract 
 
CRISPR-Cas systems confer an adaptive immunity against viruses. Following viral injection, Cas1-Cas2 
integrates segments of the viral genome (spacers) into the CRISPR locus. In type I CRISPR-Cas systems, 
efficient “primed” spacer acquisition and viral degradation (interference) require both the Cascade 
complex and the Cas3 helicase/nuclease. Here, we present single-molecule characterization of the 
Thermobifida fusca (Tfu) primed acquisition complex (PAC). We show that TfuCascade rapidly samples 
non-specific DNA via facilitated one-dimensional diffusion. Cas3 loads at target-bound Cascade and the 
Cascade/Cas3 complex translocates via a looped DNA intermediate. Cascade/Cas3 complexes stall at 
diverse protein roadblocks. In contrast, Cas1-Cas2 samples DNA transiently via 3D collisions. Moreover, 
Cas1-Cas2 associates with Cascade and translocates with Cascade/Cas3, forming the PAC. PACs can 
displace different protein roadblocks, suggesting a mechanism for long-range spacer acquisition. This 
work provides a molecular basis for the coordinated steps in CRISPR-based adaptive immunity. 
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AI.2 Introduction 
Bacteria and archaea destroy foreign nucleic acids by mounting an RNA-based CRISPR adaptive 
immune response1–3. In Type I CRISPRs, the most frequently found CRISPR sub-type in bacteria 
and archaea3,4, foreign DNAs that trigger efficient immunity can also provoke primed 
acquisition of protospacers into the CRISPR locus5–12. Both interference and primed acquisition 
require Cascade (CRISPR-associated complex for antiviral defense) and the Cas3 
helicase/nuclease. Primed acquisition also requires the Cas1-Cas2 integrase, however the 
biophysical mechanisms of how interference and primed acquisition coordinate have remained 
elusive. Here, we present single-molecule characterization of the Type I-E Thermobifida fusca 
(Tfu) primed acquisition complex (PAC). TfuCascade rapidly samples non-specific DNA for its 
target via facilitated one-dimensional diffusion. An evolutionary-conserved positive patch on 
the Cse1 subunit promotes facilitated diffusion and increases the target recognition efficiency. 
Conformational locks stabilize the complex during R-loop propagation, even on partially 
complementary DNA targets. Cas3 loads at target-bound Cascade and the Cascade/Cas3 
complex initiates processive translocation via a looped DNA intermediate. Moving 
Cascade/Cas3 complexes stall and release the DNA loop at protein roadblocks. Cas1-Cas2 
samples DNA transiently via 3D collisions, but is stabilized via protein interactions with target-
bound Cascade. Cas1-Cas2 also remains associated with Cascade/Cas3 and is further stabilized 
as part of the translocating PAC. By directly imaging all key sub-complexes involved in target 
recognition, interference, and primed acquisition, this work provides a molecular basis for the 
central steps in CRISPR-based adaptive immunity.  
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CRISPR adaptive immunity consists of three main activities: interference, primed acquisition, 
and naïve acquisition13–16. Interference provides immunity by targeting and destroying foreign 
nucleic acids that are recorded in the CRISPR locus. The CRISPR system adapts to new threats by 
acquiring and segments of foreign genetic elements into the CRISPR array, where they are 
transcribed and used to confer immunity against the invading nucleic acid17–20. In Type I 
CRISPRs, the Cascade surveillance complex initiates both interference and primed acquisition5–
12. Cascade surveils the cell for foreign DNA that is complementary to its CRISPR RNA (crRNA)17. 
An RNA-DNA loop (R-loop) between the crRNA and the duplex target DNA conformationally 
locks Cascade onto the foreign genetic element21–29. Next, target-bound Cascade loads Cas3 
nuclease/helicase, which unwinds and degrades the foreign DNA21,30–33.  
 
Primed and naïve acquisition both require the Cas1-Cas2 integrase. Cas1-Cas2 inserts new 
protospacers into the CRISPR locus in the host’s genome via a cut-and-paste transposase 
mechanism34–36. Naïve acquisition can integrate foreign nucleic acids that the cell has not 
encountered previously and requires host nucleases to produce substrates for Cas1-Cas237. In 
contrast, primed acquisition uses Cascade/Cas3 to produce protospacers that Cas1-Cas2 then 
integrates into the CRISPR locus5–11. Primed acquisition thus requires a prior record of infection 
by a related pathogen. Because primed acquisition is substantially more efficient than naïve 
acquisition, this mechanism permits the cell to rapidly adapt to phages that have acquired 
escape mutations5,9,11,38. Although the genetic and biochemical basis for primed acquisition 
have been established previously, the biophysical mechanisms underpinning interactions 
between Cascade, Cas3, and Cas1-Cas2 have remained elusive5,6,9. To address this gap, we 
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report the stepwise assembly and biophysical characterization of the Thermobifida fusca (Tfu) 
Type I-E CRISPR-Cas interference and primed acquisition machineries. Using single-molecule 
fluorescence imaging of each sub-complex, we show that Cse1 plays a key role in target 
recognition by promoting rapid scanning of foreign DNA via facilitated diffusion. After target 
recognition, Cascade recruits Cas3, and the Cascade/Cas3 interference sub-complex 
translocates via a looped DNA intermediate. Finally, we provide direct evidence that 
Cascade/Cas3 interacts with Cas1-Cas2 to form a translocating complex that combines all the 
biochemical functions required for both interference and primed acquisition.  
 
AI.3 Cse1 promotes target recognition via facilitated diffusion on non-specific DNA 
To understand how Cascade participates in both interference and primed acquisition, we first 
imaged fluorescent TfuCascade on double-tethered DNA curtains that extend the substrate in 
the absence of buffer flow39,40 (Figures AI.1 and S1). The DNA substrate (derived from 
bacteriophage ) lacked a target DNA that was complementary to the Cascade crRNA. Prior 
studies reported that the S. pyogenes Cas9 and E. coli Type I-E effector complexes sample 
protospacer adjacent motif (PAM) sites exclusively via three dimensional (3D) collisions, 
suggesting that this is a universal feature of diverse CRISPR systems41,42. Unexpectedly, 90% 
(N=258 out of 288) of TfuCascade molecules initially bound non-specific DNA and scanned the 
substrate via facilitated one-dimensional (1D) diffusion (Figure AI.1D-F). Facilitated diffusion 
can accelerate the target search dynamics, as has been observed for other DNA-binding 
proteins43. During 1D diffusion, proteins can either slide along the helical pitch of the DNA 
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backbone, or can transiently dissociate and associate with the DNA via a series of microscopic 
hops. Hopping allows proteins to efficiently search larger segments of the genome while 
frequently randomizing the spatial register between the protein and the DNA backbone (see 
below)43,44. Hopping can be observed indirectly by measuring the change in the diffusion 
coefficients at higher ionic strengths, which increase electrostatic screening between the 
protein and DNA. This results in measurably larger 1D diffusion coefficients and can be used to 
estimate the number of disrupted electrostatic charges45. Cascade diffusion coefficients 
increased with higher ionic strength, with approximately one charge screened at physiological 
ionic strength (Figure AI.1F). Cascade lacking Cse1 did not diffuse on DNA curtains. Therefore, 
we conjectured that a positive patch on the TfuCse1 outer surface (Figure AI.1A, bottom) 
promotes facilitated diffusion of Cascade during foreign DNA surveillance46. A structure-based 
multi-sequence alignment of divergent Cse1 variants revealed that the positive patch is highly 
conserved and can extend up to eight amino acids (Figure S2A)47. Notably, this positive patch is 
disrupted in the E. coli (Ec) Cse1, likely limiting the 1D scanning mode of EcCascade beyond the 
resolution of prior studies (Figure S2B)27,48–50. The TfuCse1 studied here encodes positive 
charges at five of these eight sites (Figure AI.1A). To test the importance of the Cse1 positive 
patch on facilitated diffusion, we purified Cascade harboring Cse1(5A), a variant with all five 
positive residues mutated to alanine (Figure S2B). Cse1(5A)-Cascade diffusion trajectories were 
2.6-fold shorter than the wild type complex on non-specific DNA (Figure AI.1G; 2.7 ± 0.7 sec, 
N=50 molecules vs. 7.1 ± 1.8 sec, N=100), and also had a 50-fold lower binding affinity for target 
DNA, as determined by electrophoretic mobility shift assays (EMSAs, Figures AI.1H and S2). 
Extending the positive patch to eight positive residues, Cse1(3R), did not appreciably change 
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the duration of the diffusion traces (8.9 ± 2.2 sec, N=100) and also did not affect the binding 
affinity for target DNA (Figures S2). To further probe the role of Cse1 in promoting Cascade 
diffusion, we developed a sortase-based transpeptidation strategy to fluorescently label the 
Cse1 subunit alone, or in complex with Cascade (Figure S3). Fluorescent Cse1 could bind and 
diffuse on DNA, with the longest Cse1 binding events occurring on DNA regions with the highest 
PAM density (Figure S3D-F). Cse1 diffusion trajectories were shorter than those for the Cascade 
complex at identical ionic strength, suggesting that Cascade also contributes secondary non-
specific DNA interactions (Figure S3E). A positive groove in the TfuCse2 subunit is positioned to 
interact with DNA in the Cascade-crRNA structure and may contribute additional stabilization 
during target search on non-specific DNA27,48–50. Taken together, this data shows that the 
positive channel formed on the surface of TfuCse1 is sufficient to promote facilitated diffusion 
and efficient target recognition by TfuCascade. 
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Figure AI.1. Cse1 promotes facilitated diffusion of the Cascade surveillance complex along DNA. 
(A) Top: structure of the T. fusca (Tfu) Cascade surveillance complex (PDB ID: 5U0A). Cascade consists of a crRNA, 
Cse1(blue/green), two Cse2s (yellow/tan), Cas5 (pink), six Cas7s (light/dark gray), and Cas6e (purple).  An epitope 
on the C-terminus of Cas6e was used for fluorescent labeling (star). Bottom: structure of TfuCse1 highlighting 
positive patch residues (purple). Positive patch residues that are evolutionarily conserved, but are neutral in 
TfuCse1 are shown in orange. (B) Illustration of double-tethered DNA curtains. A lipid bilayer is deposited on a 
quartz slide with a microfabricated chrome barrier (B) and pedestals (P). Phage  DNA is ligated with biotin and 
digoxigenin (dig)-terminated oligonucleotides and tethered to the lipid bilayer via a biotin-streptavidin linkage. The 
second DNA end is immobilized on pedestals coated with anti-digoxigenin antibodies. (C) Fluorescent image of 
double-tethered DNA curtains. DNA (green) is stained with a fluorescent intercalating dye (YOYO-1). Cascade 
(magenta) binds non-specifically along the DNA substrate. B: barriers; P: pedestals. (D) Illustration (top) and 
kymographs (bottom) of the indicated Cascade variants scanning DNA for targets via facilitated diffusion. White 
and red arrows mark DNA binding and release, respectively. (E) Single-particle traces showing six representative 
Cascade molecules diffusing on DNA. (F) Mean Cascade diffusion coefficients as a function of the ionic strength. N 
> 45 molecules for all conditions. Error bars: S.E.M. The linear fit (red line) estimates 0.93±0.43 (Avg ± 95% C.I.) 
Coulombic interactions are disrupted at increasing ionic strength. (G) DNA-binding lifetimes of each Cascade 
variant. The data was fit to a single exponential decay (solid lines). Half-lives ± 95% C.I. is calculated from the fit. 
(H) Cascade target binding affinities, as measured via electrophoretic mobility shift assays. Mean and S.D. are 
calculated from at least three replicates.  
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AI.4 Cascade samples potential targets via two transient intermediates 
Next, we determined how diffusing Cascade molecules recognize full and partially 
complementary DNA targets (Figure AI.2). Incubating Cascade with the target-containing DNA 
results in complexes that remain bound at the target site for > 1,900 seconds, indicating full R-
loop propagation (Figures AI.2 & S4). Direct observation of target recognition dynamics 
revealed that ~80% of Cascade-target encounters (N=313 encounters) resulted in pausing 
events longer than 800 ms (Figure AI.2C). Diffusing Cascade only pauses at full or partial 
targets; we did not observe pausing on PAM-rich, but otherwise non-specific DNA (see below). 
Cascade first recognizes the PAM via the Cse1 subunit, followed by directional extension of the 
R-loop away from the PAM and along the crRNA51,52,28,22,42. However, diffusing Cascade can 
encounter the target in two polarities—with Cse1 positioned to recognize the PAM and the 
crRNA oriented in the correct direction for R-loop propagation, or with the crRNA in the 
opposite orientation relative to the target DNA. Therefore, we also determined whether 
Cascades that encounter the target from the PAM-proximal or distal sites impact the target 
recognition frequency. Remarkably, complexes that approach from the PAM-proximal side 
were just as likely to pause at the target site as those that approach from the PAM-distal end 
(Figure AI.2D). Moreover, after the pauses, Cascade was equally likely to depart from the target 
site in either PAM-proximal or distal direction (Figure S4C). These data are consistent with 
microscopic hopping during facilitated diffusion. Hopping allows Cascade, and likely other site-
specific DNA binding proteins, to sample potential target sites with both polarities, ensuring 
efficient target recognition.  
103 
 
Figure AI.2. Cascade transiently samples target sequences via PAM-dependent R-loop propagation 
and seed-distal complementarity.  
(A) Illustration of a DNA substrate with a single Cascade target inserted 21.2 kb away from the cosL DNA end. The 
target DNA strand is shown base-paired to the crRNA (red). Numbers indicate flipped out R-loop bases. (B) Top: 
Image of Cascade (magenta) bound to the target sequence on a single-tethered DNA curtain (green). Bottom: 
histogram of Cascade binding along the DNA substrate shows a strong preference for the target site. The red line 
indicates a fit to a Gaussian curve with the center and standard deviation of the fit (error bar) indicated in the 
figure. (C) Top: illustration and kymograph of a diffusing Cascade molecule transiently pausing at the target site. 
The white and red arrows indicate the beginning and end of a pause, respectively. Bottom: single-molecule 
tracking indicates that Cascade pauses twice at the target site (dashed line). The gray band indicates the 
experimental uncertainty in defining the target site. (D) Cascade pauses with equal frequency at the target 
regardless of whether it approaches from the PAM-proximal or PAM-distal side (N=27 Cascade molecules; 227 
pauses). Error bars are generated from bootstrapping.  (E) Schematic of six DNA substrates containing a second 
Cascade target 34.5 kb away from the cosL DNA end. The second targets encode either an altered PAM or 
segments of the target DNA that are mismatched (white boxes) or complementary (green boxes) with the crRNA. 
The bottom DNA substrate does not encode any homology to the crRNA and is included as a negative control. (F) 
Pausing probability of Cascade on the six DNA substrates described in (E). Pausing distributions are fit to two 
Gaussians (red) and recover both target positions (dotted grey lines). N: number of pauses. (G) Cascade pause 
durations on the substrates shown in (E). In all but two cases, the data required a bi-exponential fit (solid lines). 
The magnitude of the second population of the two exponentials is reported. N > 95 pauses for all experiments. (H) 
Model for target recognition by diffusing Cascade surveillance complexes. The top row represents a target with 
partial complementarity, and the bottom row a target with full complementarity. Cse1 interacts with the PAM to 
begin directional unwinding of the DNA duplex. Top row: the extending R-loop is partially stabilized by salt bridges 
in TfuCse2.1 and Cse2.2 (black closed gates), but eventually collapses, causing Cascade to leave the target. Bottom: 
complete R-loop extension locks Cascade onto the DNA target, triggers a conformational change in Cse1, and 
promotes Cas3 binding (not shown). 
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Cascade is proposed to engage potential target DNA sites via a series of sequential steps that 
include PAM recognition, melting of a DNA bubble, propagation of the R-loop past a critical 8-
10 nt ‘seed’ region, and conformational locking6,22,26–28,51,52. To further probe this series of 
steps, we constructed DNA substrates that included a second target site with altered PAMs or 
partial sequence complementarity to the crRNA (Figures AI.2E and S4D). Cascade pausing at 
these partial target sites required both a PAM as well as a crRNA-complementary segment of 
target DNA. Surprisingly, scrambling the seed region only resulted in a 50% reduction of paused 
Cascade molecules relative to the perfect target sequence (Figure AI.2F). This suggests that 
Cascade can transiently recognize PAM-distal target DNA independently of the seed. Next, we 
observed how long Cascade remained associated with each of the PAM variants and partial 
target sequences (Figure AI.2G, left). Cascade pause times were best described by a bi-
exponential fit with a short, t1=1-3 sec, and a longer, t2~50 sec, half-life. The PAM controlled the 
duration and relative amplitude of the shorter timescale (t1), but not the duration of t2. The 
highest DNA-binding affinity (and strongest interference) PAM (5’-AAG) resulted in the longest 
t1 pause duration t1=2.8 ± 0.1 sec (N=656 pauses). In contrast, intermediate interference 5’-CAG 
and weakest interference 5’-AGG PAMs had short t1 pauses (t1=1.5 ± 0.1 sec; N=105 and t1=2.4 ± 
0.4 sec; N=96 pauses, respectively). Moreover, the weakest 5’-AGG PAM pause durations were 
best described by a single, short exponential decay without a long-lived state (t2). Next, we 
determined the pause duration for Cascade on a series of targets that had the strongest PAM 
(5’-AAG), but contained mismatches between the crRNA and the first, second, and third 
segments of the target DNA (Figure AI.2G, right). All DNA substrates still exhibited a short 
pause, t1=~1-2 sec. The second pause duration, t2, was ~2.6 fold shorter than the perfect target 
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for substrates with PAM-proximal and distal complementarity, but was virtually non-existent 
when the complementarity was moved to the middle segment. These data show that 
complementarity in the PAM-proximal ‘seed’ region is sufficient to induce a long-lived pause on 
the partial target as the R-loop directionally propagates away from the PAM. Unexpectedly, 
PAM-distal complementarity is also sufficient for a long-lived Cascade pause. Taken together 
with our recent structural work of TfuCascade R-loop intermediates53, these results suggest the 
model summarized in Figure AI.2H. The identity of the PAM and the first few PAM-proximal 
nucleotides initiate a short (1-3 sec) pause. This pause is likely necessary for Cse1 to insert an 
aromatic wedge into the PAM-proximal DNA duplex and melt a bubble in the target DNA26. R-
loop propagation is reversible, even on the complementary target DNA. Extension of the R-loop 
past two Cse2 salt bridges further stabilize the R-loop intermediate53. Finally, conformational 
locking of the entire Cascade complex re-orients the Cse1 N- and C-terminal lobes for Cas3 
recruitment and downstream interference and primed acquisition. 
 
AI.5 Translocating Cascade/Cas3 complexes generate tension-sensitive DNA loops 
Primed acquisition and interference both require the concerted activities of Cascade and the 
Cas3 nuclease/helicase. Therefore, we next determined the mechanism of TfuCas3 recruitment 
and translocation by imaging Cascade, Cas3, and the ssDNA product. For fluorescent imaging, 
an ATTO647N dye was directly conjugated to the C-terminus of Cas3 via sortase-mediated 
transpeptidation (Figure S5). Labeling Cas3 with a small C-terminal organic fluorophore was 
essential because the N-terminus of Cas3 interacts with TfuCas1-Cas2 (data not shown). 
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Fluorescent Cas3 localized exclusively to target-bound Cascade and remained stationary on the 
single-tethered DNA substrates with AMP-PNP, a non-hydrolysable ATP analog (Figures AI.3A 
and S5B-D). These findings are consistent with Cascade loading Cas3 onto the target DNA. In 
the presence of 1 mM ATP, Cas3 translocated towards the DNA tethering point, as expected for 
the 3’5’ directionality of the Cas3 helicase domain on the non-target strand (Figure AI.3B & 
S5)54. Remarkably, Cascade remained associated with the translocating Cas3 in 47% of all 
trajectories (Figure AI.3B). In the remaining trajectories, Cascade and Cas3 fluorescent signals 
separated within a single frame (< 200 ms), suggesting a rupture between Cascade and Cas3 
that was rapid and stochastic. After rupturing from Cas3, Cascade returned to its initial position 
at the target DNA site while Cas3 continued to translocate along the DNA substrate (Figure 
AI.3B, top). The co-translocation of the Cascade/Cas3 complex and instantaneous Cascade 
return to the target site is consistent with a looped DNA intermediate produced during DNA 
translocation, as has been proposed in other single molecule studies of E. coli Type I-E system 
(41 and Loeff et al). Tracking individual trajectories revealed an initiation phase where Cas3 
showed short bursts of translocation that were largely below our spatial resolution (Figure S6C 
and Loeff et al). Initiation lasted for 30 ± 0.8 s (N=48), followed by processive movement along 
the DNA substrate (Figure AI.3C). Cas3 translocated along the DNA substrate with a mean 
processivity of 19 ± 7kb (N=68, error bars denote S.D.) at a velocity of 89 ± 25 bp s-1 (N=68). Cas3 
interacts with the Cse1 subunit of the Cascade complex21,54,27. Guided by previous findings that 
Cas3 interacts with the Cse1 subunit of Cascade and observation that Cse1 and Cas3 are fused 
in other type I-E systems, we tested whether Cse1 is associated with translocating Cas3 after 
Cascade release31,41. Concurrent dual-color imaging of both Cse1 and Cas6e in a dual-labeled 
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(ATTO647N)Cse1-Cascade complex revealed that Cse1 always remained associated with 
Cascade as Cas3 translocated away from the effector complex (Figure S5E). These results 
provide direct evidence for retention of Cse1 in the Cascade effector complex after Cas3 
loading and translocation.  
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Figure AI.3. Processive translocation by the Cascade/Cas3 complex is impeded by DNA-binding 
proteins. 
(A) Histograms of Cas3 (top), Cascade (right), and their joint DNA-binding probability (center) indicate that Cascade 
loads Cas3 at the target site. (B) Top: illustration and kymograph of a translocating Cascade/Cas3 complex. Cascade 
remains associated with the target, causing a DNA loop to accumulate during Cas3 translocation. Bottom: Cas3 
translocating independently of Cascade. White arrows: initiation of translocation; red arrow: Cascade/Cas3 
separation. (C) Cas3 initiates translocation after a 30 ± 1 second pause (N=48). The pause data was fit to a single 
exponential decay (solid line) to calculate the half-life. Error indicates 95% C.I. (D) Top: experimental configuration 
for force-dependent Cas3 translocation experiments. The free DNA end was conjugated to a 1 µm paramagnetic 
bead and hydrodynamic force was applied via buffer flow. Increasing tension on the DNA also increases the 
frequency of independent Cas3 translocation events, suggesting rupture between the Cse1 and Cas3 protein-
protein contacts. (E) Top: illustration of the protein roadblock DNA substrate. The substrate encodes four EcoRI 
binding sites, E1 to E4, positioned 4.8 kb, 10.4 kb, 17.9 and 23.7 kb upstream of the Cascade target. The 
hydrolytically defective EcoRI(E111Q) was used as a model protein roadblock. Bottom: kymographs showing 
outcomes of collisions between translocating Cascade/Cas3 complexes (magenta) and EcoRI(E111Q) (green). In all 
examples, collisions are shown with the first EcoRI(E111Q) bound at E1. (F) Quantification of the collision 
outcomes observed in (E). (G) Cascade/Cas3 translocation velocities (left) and processivities (right) on naked DNA 
and with EcoRI(E111Q) or LacI protein roadblocks. Red diamonds indicate the mean of the distribution. For 
experiments with LacI, the DNA substrate harbored a single ideal LacO site 12.3 kb upstream of the Cascade target. 
Dashed lines indicate the locations of E1 to E4 and the red lines indicate the location of the first roadblock 
encountered by Cascade/Cas3. N > 25 for all conditions. The translocation rate was statistically indistinguishable 
for all conditions (p=0.08, 0.34, 0.42 for EcoRI.E1, EcoRI.E2, and LacI relative to naked DNA, respectively), whereas 
the processivity was significantly reduced in all roadblock experiments (p=5.7x10-20, 5.9x10-19, 1.6x10-12 for 
EcoRI.E1, EcoRI.E2, and LacI relative to naked DNA, respectively). (H) Model summarizing how Cascade/Cas3 
translocates on crowded DNA. Cascade/Cas3 extrude a DNA loop while translocating processively until a collision 
with a protein roadblock (red octagon). Cascade/Cas3 either slip back or stall at the roadblock. Cas3 can also 
separate from Cascade and an independently translocating Cas3 can push and evict the roadblock from DNA. 
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Physical interactions between target-bound Cascade and a moving Cas3 will produce a growing 
and tension-dependent DNA loop between Cse1 and Cas3 (41 and Loeff et al). To directly 
visualize these looped DNA intermediates, we used DNA substrates with one fluorescent DNA 
end positioned either upstream or downstream of translocating Cas3 (Figure S5F,G). Consistent 
with the looping model, Cas3 movement away from the free DNA end also pulls Cascade and 
the free DNA end at identical rates in the direction of Cas3 translocation (Figure S5F, N=10). 
Alternatively, if the DNA tethering geometry is reversed, then Cas3 translocation will reel in the 
free DNA end without observable Cascade movement (Figure S5G, N=10). Retraction and 
stochastic release of the free DNA end corresponded with Cas3-dependent translocation and 
Cse1-Cas3 rupture. In the cell, one or both ends of the foreign DNA are likely to be physically 
constrained (i.e., to the viral capsid during infection/package or to the transcription/translation 
machinery during viral replication)55. Processive Cascade/Cas3 translocation will thus produce 
increasing DNA tension as the DNA loop grows. To define the role of DNA tension on Cas3 
translocation, we developed a high-throughput assay to measure force-dependent 
Cascade/Cas3 loop rupture (Figures AI.3D and S5H). In this assay, streptavidin is omitted from 
the lipid bilayer. The chromium pedestals are decorated with anti-DIG antibodies and the DNA 
is immobilized on the pedestals by its DIG end. The second, biotinylated DNA end is conjugated 
to 1 µm streptavidin-coated paramagnetic beads. These beads increase the hydrodynamic drag 
experienced by DNA molecules under mild buffer flow. Increasing the buffer flow rate 
(hydrodynamic force) correspondingly increases the force applied on the DNA (Figure S5I). At 
an applied force of 0.7 pN, 53% (N=30) of Cascade/Cas3 complexes translocate together for the 
duration for the entire trajectory. Increasing the applied force resulted in substantially fewer 
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looped Cascade/Cas3 complexes; only 11% (N=18) of complexes translocated together at 20 pN 
of applied force (Figure AI.3D). We conclude that Cascade/Cas3 interactions rupture as tension 
accumulates between the moving Cas3 and stationary Cascade. 
In the cell, the single-stranded DNA (ssDNA) generated via Cas3 helicase and nuclease activities 
will be rapidly bound by single-stranded DNA binding protein (SSB). We therefore imaged 
ssDNA by adding SSB-GFP into the flowcell, and we also determined whether SSB regulates 
Cas3 activities (Figure S6). The intensity of one SSB tetramer on a short ssDNA overhang was 
used to estimate the number of SSBs associated with each Cas3 (Figure S6A,B). Interestingly, 
SSB-GFP signal accumulated at Cascade/Cas3 complexes prior to processive translocation 
(Figure S6C). These puncta required ATP and were not observed when either Cas3 or ATP were 
omitted from the flowcells (data not shown). The Cas3 and ATP-dependent generation of 
ssDNA suggests that Cas3 was translocating distances that were below the ~500 bp resolution 
of these assays. Consistent with this hypothesis, we occasionally observed repetitive >500 bp 
Cas3 translocation and slipping that was coincident with a growing SSB-GFP signal (Figure S6C). 
Consistent with our observations, a smFRET-based study with EcCas3 also observed Cas3 
slipping and looped DNA intermediates during translocation (Loeff et al). Moreover, the SSB-
GFP signal only increased moderately during processive Cas3 translocation, and never reached 
full SSB saturation that would be expected if dsDNA were converted to ssDNA, suggesting Cas3 
produces short tracts of ssDNA (N=36; Figure S6D). These results do not stem from SSB 
inhibition of Cas3, as neither velocity nor processivity were reduced with SSB added to the 
flowcell (Figure S6E) (Loeff et al). Taken together, our results are consistent with initiation via 
repetitive rounds of Cas3 slipping and restart, followed by processive Cas3 helicase activity 
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followed by reannealing of the ssDNA into dsDNA. The Cas3 nuclease domain likely nicks the 
double-stranded DNA substrate and occasionally produces short tracts of ssDNA that are 
rapidly coated by SSB. 
 
AI.6 Translocating Cascade/Cas3 is blocked by other DNA-binding proteins 
In the cell, DNA is decorated with transcription factors and other DNA-binding proteins. Cas3 
will likely encounter these obstacles during processive (>10 kb) translocation. We therefore 
determined if two site-specific DNA binding proteins—hydrolytically defective EcoRI (E111Q) 
and Lac repressor (LacI)—influence processive Cas3 translocation (Figure AI.3E-G). We first 
observed Cas3 interactions with fluorescent EcoRI (E111Q) bound specifically to the four EcoRI 
binding sites on these DNA substrates. The closest two sites, EcoRI.E1 and EcoRI.E2, are 4.8 kb 
(E1) and 10.4 kb (E2) upstream of the Cascade target, respectively (Figure AI.3E, top). To assay 
Cas3 vs. EcoRI(E111Q) collisions, fluorescent Cascade and EcoRI(E111Q) were incubated with 
the DNA prior to assembling DNA curtains. Cas3 was introduced with ATP, and translocation 
was monitored via imaging of the Cascade/Cas3 looping complex. EcoRI(E111Q) blocked 100% 
(N=76/76 molecules) of all Cascade/Cas3 complexes. The most frequent outcome, accounting 
for 51% of all collisions (N=39/76), was Cascade/Cas3 stalling at the roadblock (Figures AI.3E,F). 
Other outcomes included stalling followed by rupture of the Cas3-Cse1 complex (33%), or loop 
release and re-looping by the same Cascade/Cas3 complex (8%). Interestingly, after Cas3 leaves 
Cascade, ~8% (N=6/76) of the Cas3 complexes appeared to push EcoRI(E111Q) off its target 
site. We never observed roadblock pushing by the entire Cascade/Cas3 complex, suggesting 
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that Cas3 alone may be more active at removing protein roadblocks. To differentiate the effects 
of the roadblock from the natural processivity of Cascade/Cas3 on naked DNA, we focused our 
analysis on Cascade/Cas3 complexes that encountered either of the first two occupied 
EcoRI(E111Q) binding sites. The observed velocity was statistically indistinguishable to that on 
naked DNA. However, translocation was blocked by the protein roadblock (Figure AI.3G, S7). 
LacI, located 12.3 kb upstream of the Cascade target, also acted as a strong roadblock to 
Cascade/Cas3 translocation, with 100% (N=28/28) of collisions resulting in stalling and frequent 
Cascade/Cas3 loop release (Figure S7). In sum, the Cascade/Cas3 complex processively 
translocates on naked DNA, but is blocked by other DNA-binding proteins (Figure AI.3H). 
Roadblocks may promote Cas3 slipping and re-looping, as has been observed in this study and 
with EcCas3 (Loeff et al). Cascade/Cas3 may also stall frequently during translocation on 
crowded DNA in vivo. This stalling may provide additional time for the Cas3 nuclease activity to 
degrade foreign genetic elements and may also explain the degradation and primed acquisition 
hotspots reported in prior in vivo studies5,11,38. Stochastic rupture of the Cse1-Cas3 interface will 
eventually liberate freely-translocating Cas3 to push and evict roadblocks during CRISPR 
interference (Figure AI.3G). 
 
AI.7 Cas1-Cas2 associates with Cascade/Cas3 in the Primed Acquisition Complex (PAC) 
Primed acquisition requires Cascade, Cas3, and the Cas1-Cas2 integrase5–12. However, the 
functions of Cas1-Cas2 in primed acquisition have only been assayed indirectly. Here, we 
observed the assembly and translocation of a ~710 kDa primed acquisition complex (PAC), 
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consisting of Tfu Cas1-Cas2, Cascade, and Cas3 (Figure AI.4). For single molecule imaging, the 
Cas2 N-terminus was fluorescently labeled via sortase-mediated transpeptidation (Figure S8). 
As expected from biochemical and structural studies of diverse Cas1-Cas2 integrases, TfuCas1-
Cas2 also formed a heterodimer with a (Cas1)2-(Cas2)4 stoichiometry (Figure S8B). Cas1-Cas2 
transiently bound the DNA substrate with a half-life of ~5.9 ± 0.1 seconds (N=38) (Figures AI.4A 
and AI.4D) and lacked a discernable DNA sequence preference (Figure S8D). We next sought to 
determine how Cas1-Cas2 interacts with the Cascade surveillance complex (Figure AI.4B). Three 
lines of evidence indicated that Cas1-Cas2 forms a long-lived complex with both target-bound 
and diffusing Cascade complexes. First, Cas1-Cas2 co-localized with Cascade that was pre-
loaded on the target site, and the lifetime of this Cas1-Cas2 on DNA increased ~5.8-fold relative 
to Cas1-Cas2 in the absence of Cascade (Figures AI.4B and S8E). Second, pre-incubating 
fluorescent or unlabeled Cascade with fluorescent Cas1-Cas2, resulted in Cascade/Cas1-Cas2 
complexes that diffused on non-specific DNA and could recognize the Cascade target sequence 
(Figure S8F). Third, Cascade could be pulled down with bead-immobilized TfuCas1-Cas2 (Figure 
S8G). Next, unlabeled Cas3 was added to the pre-assembled Cascade/Cas1-Cas2 sub-complex 
and the entire primed acquisition complex (PAC) was imaged via dual-color illumination. 
Directional translocation of the PAC away from the target site confirmed the presence of Cas3 
(Figure AI.4C). Importantly, the PAC remained stationary when ATP was substituted for the 
non-hydrolyzable AMP-PNP in the imaging buffer (data not shown). All translocating PACs 
retained Cas1-Cas2 for the duration of the entire trajectory (N=40), indicating that Cas1-Cas2 is 
further stabilized within the PAC (Figures AI.4D & AI.4E) relative to the Cascade/Cas1-Cas2 sub-
complex. All translocating PACs moved towards the DNA tether at a mean velocity of 84 ± 28 bp 
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s-1 (N=40; error indicates S.D.), which was statistically indistinguishable from the velocity 
observed for Cascade/Cas3 (Figure AI.4F). In contrast, the PAC processivity was 25% lower than 
the Cascade/Cas3 complex (15.5 ± 5.6 kb for the PAC, N=40; p=0.015 relative to Cascade/Cas3). 
Whereas ~50% of Cascade/Cas3 complexes eventually showed Cse1-Cas3 rupture and 
independent Cas3 translocation, we did not see any independently translocating Cas1-
Cas2/Cas3 sub-complexes under identical force and imaging conditions (Figure AI.4G, N=40). 
Taken together, these results suggest that the Cas1-Cas2 is a core subunit of PAC, where it is 
stabilized by direct interactions with Cascade. Additional interactions between Cas1-Cas2 and 
Cas3, as well as the forked DNA that emerges from the Cas3 exit channel also likely contribute 
to Cas1-Cas2 retention in the PAC. 
The formation of the PAC in vivo was also tested via BiFC between Cascade and Cas1 in the 
presence of Cas3 and target DNA (Figure 4H). Induction of all PAC components produced a 
fluorescent signal between Cas1-Cas2 and Cascade, but only in the presence of a high-affinity 
target. In contrast, Cas1-Cas2 bound to Cascade independently of a high-affinity DNA target in 
the absence of Cas3 (Figure 4I). These data suggest that the PAC organizes around the target 
DNA and that Cas3 may inhibit the ability of Cas1-Cas2 to bind Cascade in the absence of a 
target DNA. Taken together, our results demonstrate that Cas1-Cas2 is a core subunit of the 
PAC, where it is stabilized by direct interactions with Cascade. Additional contacts between 
Cas1-Cas2 and Cas3, as well as the forked DNA that emerges from the Cas3 exit channel may 
contribute to Cas1-Cas2 retention in the PAC.   
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Figure AI.4. Cas1-Cas2 forms a primed acquisition complex (PAC) with Cascade and Cas3.  
(A) Illustration (top), kymograph (middle), and quantification (bottom) showing Cas1-Cas2 randomly sampling DNA 
via 3D collisions. White arrows: Cas1-Cas2 binding, red arrows: Cas1-Cas2 dissociation. Cas1-Cas2 does not show a 
DNA sequence preference. The dashed red line and gray band represent the Cascade target site, as defined in 
Figure 2. (B) Illustration (top) and kymographs of Cas1-Cas2 (green) recruitment to Cascade (magenta) at the target 
sequence. (C) Illustration and a kymograph of the primed acquisition complex (PAC) consisting of Cascade, Cas1-
Cas2, and Cas3 processively translocating along the DNA. Cascade (magenta) and Cas1-Cas2 (green) are 
fluorescently labeled while the presence of dark Cas3 is observed via translocation of the entire complex. (D) DNA-
binding lifetimes of Cas1-Cas2 on DNA (blue), as part of the Cascade/Cas1-Cas2 sub-complex (red), and the PAC 
(green). The data is fit to a single exponential decay. A constant was also included in the Cascade/Cas3 and PAC 
fits. Error: 95% C.I. (E) Representative traces of the PAC translocating on DNA. Cascade (magenta) and Cas1-Cas2 
(green) are fluorescently labeled. The target sequence is shown as a dashed red line and solid gray band. (F) The 
mean PAC velocity (red diamond) was statistically indistinguishable from Cascade/Cas3 (N≥39 for all datasets; 
p=0.34). Mean PAC processivity was reduced compared to Cascade/Cas3 (p=0.015). Red diamonds indicate the 
mean of the PAC distribution. The mean and S.D. of the Cascade/Cas3 distributions are indicated by the solid and 
dashed lines, respectively. (G) Left: The PAC translocates exclusively via a DNA looping mechanism. Right: 
termination outcomes for translocating Cascade/Cas3 and PAC complexes. Error bars generated via bootstrapping. 
(H) BiFC assay showing the PAC forms in vivo.  (I) Cascade interacts with Cas1-Cas2 without a target DNA. Scale 
bars, 10 μm and 2 μm for the insets. 
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AI.8 Cascade/Cas3 Stalls and Causes DNA Breaks after Colliding with Other DNA-Bound 
Proteins 
Cas3 likely encounters RNA polymerases (RNAPs), transcription factors, and other DNA-binding 
proteins during processive (>10 kb) translocation. We therefore determined the outcomes of 
collisions between Cas3 and three site-specific DNA binding proteins—hydrolytically defective 
EcoRI (E111Q), Lac repressor (LacI), and stalled EcRNAP (Figures 5 and S6). EcoRI (E111Q), LacI, 
and RNAP bind their target sites with pM-nM affinity and are frequently used as model 
roadblocks on DNA (Finkelstein and Greene, 2013). We first observed Cas3 interactions with 
fluorescent EcoRI (E111Q), which bound specifically to four EcoRI binding sites on the DNA 
(Figure AI.5A, top). To assay Cas3 versus EcoRI (E111Q) collisions, fluorescent Cascade and 
EcoRI (E111Q) were incubated with the DNA prior to assembling DNA curtains. Cas3 was 
introduced with ATP, and translocation was monitored via imaging of the Cascade/Cas3 looping 
complex. EcoRI (E111Q) blocked 100% (n = 76/76) of all Cascade/Cas3 complexes. The most 
frequent outcome, accounting for 51% of all collisions (n = 39/76), was Cascade/Cas3 stalling at 
the roadblock (Figures 5A and 5F). Other outcomes included stalling followed by a single-frame 
release of Cascade/Cas3 back to the initial target site (33%), or re-looping by the same 
Cascade/Cas3 complex (8%). In the rare event of Cas3 dissociation from Cascade before 
collision with the roadblock, the freely moving Cas3 could push EcoRI (E111Q) off its target site. 
We never observed roadblock pushing by the entire Cascade/Cas3 complex, suggesting that 
Cas3 alone may be able to remove protein roadblocks. To differentiate the effects of the 
roadblock from the natural processivity of Cascade/Cas3 on naked DNA, we focused our 
analysis on Cascade/Cas3 complexes that encountered either of the first two occupied EcoRI 
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(E111Q) binding sites (E1 and E2 in Figure AI.5). The observed velocity was statistically 
indistinguishable from Cas3 on naked DNA. However, translocation was blocked by the protein 
roadblock (Figure AI.5B and S6C). 
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Figure AI.5. Differential Outcomes of Translocating Cascade/Cas3 and the PAC at Protein 
Roadblocks 
(A) Top: Illustration of four EcoRI binding sites, E1 to E4, upstream of the Cascade target. Bottom: Outcomes for 
collisions between translocating Cascade/Cas3 complexes (magenta) and EcoRI(E111Q) bound at E1 (green).  (B) 
Cascade/Cas3 translocation velocities (left) and processivities (right) on naked DNA or with EcoRI(E111Q) 
roadblocks. Red diamonds: mean of the distribution. Dashed lines: locations of E1 to E4. Red line: the location of 
the first roadblock encountered by Cascade/Cas3. n > 25 for all conditions. Cas3 velocity was statistically 
indistinguishable for all conditions (p = 0.08, 0.34 for E1 and E2 relative to naked DNA, respectively), whereas the 
processivity was significantly reduced in all roadblock experiments (p = 5.7 × 10−20, 5.9 × 10−19 for E1 and E2 
relative to naked DNA, respectively). (C) Position of DSBs induced by Cas3 nuclease activity (n ≥ 10).  (D) The PAC 
(magenta) pushes EcoRI(E111Q) (green).  (E) Velocities (left) and processivities (right) of the PAC in the absence 
and presence of EcoRI(E111Q). Both velocities and processivities were reduced with a roadblock compared to 
naked DNA (p = 1.9 × 10−3 and p = 4.9 × 10−5 for velocity and processivity, respectively). (F) Outcomes of collisions 
with EcoRI(E111Q).  (G) The PAC causes less frequent DSBs on both naked DNA and at a protein roadblock. Error: 
95% CI of a single exponential fit.  (H) Top: Cascade/Cas3 stalls and creates a DSB at roadblocks. Bottom: The PAC 
can push through roadblocks to acquire additional protospacers. 
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We also tested two additional protein roadblocks that Cascade/Cas3 would likely encounter in 
the cell. Lac repressor (LacI) is a bacterial transcription factor that binds its operator site with 
picomolar affinity and is frequently used as a potent roadblock for DNA motor proteins 
(Finkelstein and Greene, 2013). LacI, located 12.3 kb upstream of the Cascade target, also 
blocked Cascade/Cas3 translocation with 100% (n = 28/28) of collisions resulting in stalling and 
frequent Cascade/Cas3 loop release (Figures S6A–S6C). Finally, we tested conflicts between 
Cascade/Cas3 and the host RNAP, which is required for early transcription of all foreign DNAs. 
While Cascade/Cas3 was able to push stalled RNAP (31% of collisions), the most frequent 
outcome was still Cascade/Cas3 stalling at an EcRNAP (67%) (Figures S6D and S6E). In sum, the 
Cascade/Cas3 complex processively translocates on naked DNA but is largely blocked by other 
DNA-binding proteins (Figure AI.5H). 
We reasoned that stalled Cas3 may create a double-stranded DNA break (DSB) through 
concerted nicking via its nuclease activity at the protein roadblock. To test this, we determined 
the location of Cas3-induced DSBs and the rate of their occurrence with and without the EcoRI 
roadblock. In the single-molecule assay, DSBs are visualized as a sudden (single-frame) 
shortening of the DNA molecule along with a loss of the Cascade/Cas3 signal, or by visualization 
of the cleaved DNA via a DNA intercalating dye (YOYO-1). The lifetime of Cascade/Cas3 on DNA 
was significantly shorter in the presence of the EcoRI(E111Q) roadblock relative to naked DNA 
(Figure AI.5G). Cascade dissociation occurred simultaneously with DNA cleavage and required 
the addition of Cas3 and ATP (Figure S6F). In the absence of any protein roadblocks, DSBs were 
distributed throughout the DNA. However, Cas3-induced DSBs were predominantly at the 
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EcoRI.E1 and EcoRI.E2 sites when EcoRI(E111Q) was deposited on the DNA (Figure AI.5C). These 
results indicate that stalled Cascade/Cas3 complexes cleave DNA at protein roadblocks. The 
resulting free DNA end may then be further processed by RecBCD and other host nucleases. 
AI.9 The PAC Pushes through DNA-Binding Proteins to Search for Downstream Protospacers 
Primed acquisition can occur kilobases away from the Cascade target site, indicating that the 
PAC is also likely to encounter protein obstacles as it translocates on DNA (Semenova et al., 
2016). Therefore, we tested how the PAC responds to the EcoRI(E111Q) and stalled RNAP 
protein roadblocks. We first incubated Cascade and EcoRI(E111Q) with the DNA substrate. 
Next, fluorescent Cas1-Cas2 was injected into the flowcell, followed by Cas3 and 1 mM ATP. 
Translocation of the PAC was observed as directional movement of Cascade or Cas1-Cas2 away 
from the target site. The most common outcome of PAC-EcoRI(E111Q) collisions was pushing of 
the roadblock away from its high-affinity binding site (68% of molecules; n = 24 out of 35) 
(Figures 5D and 5F). This outcome was markedly different from the Cascade/Cas3-EcoRI(E111Q) 
collisions, which always blocked translocation (Figure AI.5F). Although the PAC could push 
EcoRI(E111Q), its velocity and processivity decreased significantly relative to the PAC on naked 
DNA (p = 1.9 × 10−3 relative to PAC and p = 4.9 × 10−5 relative to PAC, respectively) (Figure 5E). 
The PAC lifetime was essentially unchanged in the presence of protein roadblocks, suggesting 
that Cas3-induced DSBs were also significantly downregulated in the context of the PAC (Figure 
5G). The PAC could also push promoter-engaged RNAP 63% of the time, suggesting that the 
PAC is likely able to strip diverse protein roadblocks from cellular DNA (Figure S6). The ability of 
the PAC to push through protein roadblocks explains the acquisition of additional protospacers 
relatively far from the Cascade target site (Semenova et al., 2016). 
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AI.10 Discussion 
Here, we directly observe the first steps of target recognition and processing by the Tfu Type I-E 
CRISPR-Cas system (Figure AI.6). An evolutionarily conserved positive patch on the outer 
surface of Cse1 and positive residues in Cas7 promote facilitated diffusion of Cascade during 
target search. Neutralizing mutations in these positive patches reduce the lifetimes of diffusing 
Cascade complexes on non-specific DNA and decrease the in vivo interference efficiency. 
Facilitated diffusion is likely a conserved search mechanism among all CRISPR systems (206, 
207). Cascade target recognition and stable R-loop locking proceeds via at least two temporally 
distinct intermediates. The first of these intermediates initiates PAM-proximal opening of the 
DNA bubble and sampling of the target DNA “seed” region. The second, longer-lived 
intermediate includes R-loop propagation and additional stabilization via Cse2 salt-bridges. 
Complexes that cannot fully recognize the R-loop dissociate from the DNA target and continue 
to scan for targets. After target recognition, Cascade recruits Cas3 helicase/nuclease and the 
Cascade/Cas3 complex translocates in a 3′ to 5′ direction on the non-target strand. Cascade 
remains associated with the target, causing a DNA loop to develop between Cas3 and a target-
bound Cascade. This protein interaction ruptures in a stochastic and force-dependent manner, 
with Cas3 occasionally translocating independently of Cascade. The Cascade/Cas3 complex is 
highly processive on naked DNA but is blocked by other DNA-binding proteins. Cascade/Cas3 
stalling at protein roadblocks allows for iterative nicking by Cas3 and subsequent cleavage of 
the DNA strand. The resulting DSB can then be further processed by RecBCD and other host 
nucleases. In contrast, freely moving Cas3 can push protein roadblocks from their DNA-binding 
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sites. Clearing protein roadblocks by Cas3 could improve the interference efficiency on crowded 
DNA. 
Primed acquisition also requires the Cas1-Cas2 integrase. Here, we provide the first direct 
evidence that Cas1-Cas2 is stabilized on DNA via physical interactions with Cascade. Cascade 
forms the keystone of the PAC, as Cas3 and Cas1-Cas2 both require Cascade for stable 
association with the target DNA. Our data suggest that the PAC can assemble via two routes 
that include initial recruitment of either Cas3 or Cas1-Cas2 to target-bound Cascade, followed 
by addition of the remaining sub-complex (Figure AI.6). Further support for this assembly 
comes from the type I-F system, where Cas3 is expressed as a direct fusion with Cas2. 
Finally, we demonstrate that the PAC can displace other DNA-binding proteins as it searches for 
downstream protospacers. Cas1-Cas2 harbors a PAM-decoding center, initially identified in the 
structure of the EcCas1-Cas2 complex, that is also conserved in TfuCas1-Cas2 (Data S1) (89). The 
Cas1-Cas2 PAM decoding center may be able to scan, capture, and excise foreign DNAs as they 
emerge from Cas3 within the PAC. This would likely involve the Cas1 nuclease, as the Cas2 
nuclease is structurally occluded and dispensable for integration in vivo (21, 89, 205). 
Alternatively, further processing by RecBCD and other host nucleases may produce short DNA 
fragments for integration by Cas1-Cas2 nuclease. 
Two models have recently been proposed to account for how interference and primed 
acquisition are coordinated. One model suggests that Cse1 conformational changes recruit a 
Cas3/Cas1-Cas2 sub-complex during primed acquisition (82, 208). Cas3/Cas1-Cas2 then moves 
bi-directionally on the DNA to acquire new spacers. However, spacers are preferentially 
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selected from the same strand as the original Cascade target site, suggesting the prime 
acquisition machinery might processively translocate in one direction along the DNA to acquire 
additional spacers (95). Additionally, a recent single-molecule magnetic tweezers paper found 
primed acquisition occurs independently of the Cse1 conformational changes (209). An 
alternative model suggests Cas3 produces DNA cleavage products that Cas1-Cas2 can further 
process and integrate into the CRISPR locus (85). Our data reconcile these competing models by 
showing that Cas1-Cas2 forms a complex with Cascade/Cas3, allowing for Cas3 cleavage 
products to be positioned for direct uptake by Cas1-Cas2. Additional structural and biochemical 
studies will be required to address how Cas1-Cas2 selects protospacers during PAC 
translocation and how these protospacers are subsequently integrated into the bacterial 
genome.   
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Figure AI.6. Stepwise Assembly of CRISPR-Associated Sub-complexes in Interference and 
Spacer Acquisition 
(I) Cascade surveils foreign DNA via a combination of facilitated 1D diffusion and hopping. (II) 
Target-bound Cascade can interact with Cas1-Cas2 and Cas3 to assemble the PAC. (III) The PAC 
samples DNA for possible protospacers during processive translocation. (IV) Alternatively, Cas3 
induces a double-stranded DNA break, likely at a protein roadblock. The free DNA ends may be 
further processed by RecBCD or other host nucleases to generate pre-spacers for adaptive 
immunity. (V) In naive acquisition, RecBCD degrades foreign DNA into short oligonucleotide-size 
fragments. Cas1-Cas2 integrates some of these fragments into the CRISPR locus. 
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AI.11 Methods 
Protein Cloning and Purification 
Thermobifidua fusca (Tfu) Cascade54, TfuCas354, E. coli (Eco) SSB59,  EcoSSB-GFP60, Eco 3xHA-
EcoRI(E111Q)60, Eco 3xHA-LacI60, sortase variants61–63 and SUMO protease64 were purified as 
described previously. For fluorescent labeling, the Cas6 subunit encoded a 3xFLAG epitope 
tag53. TfuCse1 variants with mutated positive patch residues were cloned by using QuickChange 
multi-site mutagenesis (Agilent) using oligos MB75, MB76, MB77 & MB78 and MB79 & MB80 
for Cse1(5A) and Cse1(3R) respectively (Table 1). Plasmids harboring mutagenized Cse1 (pIF291 
for Cse1(5A) or pIF292 for Cse1(3R)) were used to purify Cascade variants following the same 
protocol as the wild type complex. For fluorescent Cas2 labeling, three glycines were added at 
the N-terminus using oligos MB069 and MB070 to generate plasmid pIF212 (NEB Q5 
mutagenesis kit). Fluorescent Cas3 was prepared by adding LPETG-TwinStrep to the C-terminus 
with oligos MB073 and MB074 to generate plasmid pIF218. 
TfuCas3 was also purified using a M9 minimal media excluding trace metals. For this 
purification, Cas3 containing an N-terminal TwinStrep-SUMO-fusion was expressed from a pET-
28b expression vector. Starter cultures were prepared by growing 5mL of LB with 50 μg mL-1 
kanamycin overnight at 37°C.  The starter was then transferred to 100 mL M9 containing 50 μg 
mL-1 kanamycin and grown overnight at 37°C. The 1 L expression cultures of M9 containing 50 
μg mL-1 kanamycin were seeded with 25mL of the overnight M9 starter and were grown at 37°C 
to an O.D.600 ~ 0.6. Cultures were induced with 1 mM of Isopropyl β-D-1-
thiogalactopyranoside (IPTG), 1 µM CoCl2 was added at this time and the cultures were grown 
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overnight at 22°C. Cells were pelleted and resuspended in 35 mL of Buffer A (30 mM HEPES [pH 
7.5], 150 mM NaCl) to be lysed via sonication. After ultracentrifugation, clarified lysate was 
placed over a 5 mL Strep-Tactin Superflow 50% suspension (IBA Life Sciences, 2-1206-010) 
gravity column equilibrated in Buffer A. The column was washed with 100 mL of Buffer A and 
the protein was eluted with 20 mL of Buffer B (30 mM HEPES [pH 7.5], 150 mM NaCl, 5 mM 
desthiobiotin). After elution, Cas3 was spin concentrated with a (10 kDa) Amicon Ultra-15 
Centrifugal Filters (EMD Millipore, UFC903024) and SUMO protease was incubated with the 
protein overnight. Cas3 was isolated on a HiPrep Sephacryl S-200 HR column (GE, 17116601) 
pre-equilibrated in Buffer A.  Peak fractions were concentrated to 25 µM and frozen with liquid 
nitrogen. 
Tfu Cas1 and Cas2 were cloned into pET expression vectors containing an N-terminal His6-
SUMO-fusion (pIF201 and pIF202 for Cas1 and Cas2, respectively). Cas1 and Cas2 were purified 
separately following the same protocol: 1 L of LB supplemented with 50 μg mL-1 kanamycin was 
seeded with 20 mL of overnight culture. Cultures were grown at 37°C to an O.D.600 ~ 0.6 and 
induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). The temperature was 
reduced to 18°C and growth continued for 18 hours. After expression, cells were pelleted by 
centrifugation and resuspended in 35 mL of Nickel Buffer A (20 mM HEPES [pH 7.5], 10 mM 
Imidazole, 500 mM NaCl). Cells were lysed by a pressure homogenizer, and cellular debris 
pelleted via ultracentrifugation. The clarified lysate was run over two tandem 1 mL His-Trap HP 
ion affinity columns (GE, 29-0510-21) pre-equilibrated in Nickel Buffer A. The His-Trap column 
was washed with 40 mL of Nickel Buffer A and Cas1 or Cas2 was eluted with a 20 mL gradient to 
100% Nickel Buffer B (20 mM HEPES [pH 7.5], 500 mM imidazole, 500 mM NaCl). SUMO 
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protease was added to the reaction in 1:50 molar ratio with Cas1 or Cas2 and the mixture was 
dialyzed against 2 L of Nickel Buffer A overnight. The Cas1-Cas2 complex was assembled by 
mixing Cas1 and Cas2 at a 4:1 molar ratio and incubating for 1 hour at 4°C. The complex was 
resolved over a HiPrep Sephacryl S-200 HR column (GE, 17116601) pre-equilibrated in Gel 
Filtration Buffer (20 mM HEPES [pH 7.5], 500 mM NaCl, 10% glycerol). 
Sortase labeling for single-molecule imaging 
Peptide synthesis.  
Peptides were synthesized using the Liberty Blue Automated Microwave Peptide Synthesizer 
(CEM Corporation) using manufacturer-suggested protocols. Analytical HPLC characterization of 
peptides was performed using an Agilent Zorbax column (4.6 x 250 mm; 10 mL min-1, 5-95% 
MeCN or MeOH (0.1 % trifluoroacetic acid (TFA) or formic acid (FA)) over 60-90 minutes). A 
Gemini C18 3.5 micron 2.1 x 50 mm was used for online separation; 0.7 mL min-1, 5-95% MeCN 
(0.1 % formic acid) in 12 min. An Agilent Technologies Accurate-Mass LC/MS (model #6530) was 
used for high-resolution mass spectra of purified peptides. All solvents were HPLC grade. 
LPETGG was synthesized using 100 µmole Fmoc-Gly-Wang resin (NovaBiochem by sequential 
coupling of the Nα-Fmoc-amino acid (P3 Biosystems) (0.2 M, 3 ml) in DMF in the presence of DIC 
(Chem-Impex Inc.) (1M, 1 mL) and ethyl (hydroxyimino)cyanoacetate (1M, 0.5 mL).  After final 
deprotection, the resin was washed three times with 20 mL DMF (Fisher), AcOH, DCM, and 
MeOH and dried under vacuum. The peptide was cleaved from resin in TFA, water, and 
triisopropylsilane (TIPS) (95:2.5:2.5) for 3 hours. TFA was removed by flow of nitrogen, and the 
peptide precipitated with -20°C diethyl ether.  Peptide was purified by preparative HPLC 
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(gradient elution, 5-95% MeOH in H2O w/ 0.1% FA).  Organic solvents were removed by rotary 
evaporation. Aqueous remnants were frozen at -70°C and lyophilized overnight.  
To make Atto647-LPETGG, 5.0 mg of NHS-Atto647N (Atto-Tec) was added to 4.4 mg LPETGG in 
1.0 ml of anhydrous DMF.  Next, 3.0 μL of N,N-Diisopropylethylamine (Sigma Aldrich) was 
added. The reaction was placed on a shaker for 3 hours and monitored by LC/MS. Crude 
mixture was purified directly by preparatory HPLC (5-95% MeOH in H2O w/ 0.1% FA). Organic 
solvents were removed by rotary evaporation, aqueous remnants were frozen at -70 °C and 
lyophilized overnight. Product was isolated as the formic acid salt.   
Fmoc-GGGK was synthesized following the procedure described previously, omitting the final 
Fmoc deprotection step.  Peptide was purified by preparative HPLC (gradient elution, 5-95% 
MeOH in H2O w/ 0.1% FA).  Organic solvents were removed by rotary evaporation, aqueous 
remnants were frozen at -70 °C and lyophilized overnight. Procedure for making GGGK-
Atto647N was performed similarly to Atto647-LPETGG. The reaction was complete after 3 
hours. To the crude mixture was added a solution of 20% piperidine in DMF (1.0 ml) and stirred 
for 20 minutes, deprotecting the N-terminus.  Crude mixture was purified directly by 
preparatory HPLC (5-95% MeOH in H2O w/ 0.1% formic acid). ). Organic solvents were removed 
by rotary evaporation, aqueous remnants were frozen at -70 °C and lyophilized overnight.  
Product was isolated as the formic acid salt 
Sortase labeling 
For fluorescent labeling, Cse1 and Cas2 were purified with an N-terminal GGG residues after the 
SUMO tag and Cas3 was purified with a C-terminal LPETGG-TwinStrep motif. Sortase labeling 
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was optimized for each protein by varying the temperature, labeling time, and sortase 
variant61–63. Cse1 was labeled by incubating 48 µM Cse1 with 50 µM sortase(5M), 10 mM CaCl2, 
250 µM (Atto647N)-LPETGG fluorescent peptide, and 60 µM SUMO protease for 12 hours at 
4˚C. Immediately following fluorescent labeling, Cse1 was separated from the free peptide and 
sortase on a Sephacryl S-200 HR column (GE) using glycerol free Gel Filtration Buffer. 
Fluorescent Cse1 was then reconstituted with the rest of the Cascade complex in a 1:1 ratio 
through a step-down NaCl dialysis (500 mM NaCl to 150 mM NaCl), and the full complex was 
isolated using a HiPrep Sephacryl S-200 HR column (GE) with TS Buffer (10 mM Tris-HCl [pH 
7.5], 150 mM NaCl, 5 mM DTT).  
Fluorescent Cas2 was prepared by cloning a C-terminal GGG purified similar to wild type Cas2 
with the following modification. After SUMO proteolysis, 20 μM of GGG-Cas2 was incubated 
with 100 μM sortase(7M) and 100 μM (Atto647N)-LPETGG fluorescent peptide at 4 °C for 1 
hour along with of 5 mM CaCl2. Fluorescent Cas2 was separated from the free peptide and 
sortase on a HiPrep Sephacryl S-200 HR column with Gel Filtration Buffer. Fluorescently labeled 
Cas3 was generated by incubating 20 μM of Cas3-LPETGG-TwinStrep with 100 μM sortase(7M) 
and 100 μM GGGK-(Atto647N) fluorescent peptide at 15 °C for 1 hour along with 5 mM of 
CaCl2. Fluorescent Cas3 was separated from the free peptide and sortase using a HiPrep 
Sephacryl S-200 HR column with Gel Filtration Buffer containing 150 mM NaCl.  
Antibodies 
Cascade was fluorescently labeled with mouse anti-FLAG M2 (Sigma, F3165) via a 3xFLAG 
epitope tag on the Cas6 subunit53. For single-molecule imaging, antibodies were conjugated to 
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605 nm or 705 nm quantum dots (QDs) following published protocols (Thermo Fisher Scientific) 
45,59. QD-conjugated antibodies were stored in PBS Buffer (pH 7.2, with 2 mM sodium azide) at 
4°C. The following antibodies were used for Westerns and co-IP experiments with Cas2, Cas3-
6xHis, and Cascade-1xFLAG, respectively: 6xHis Monoclonal Antibody (Albumin Free, Clontech, 
631212) and DYKDDDDK Tag Antibody (Cell Signaling Technology, 2368S) 
Electrophoretic mobility shift assay (EMSA) 
All EMSAs were performed with Cy5-labeled DNA substrates that were generated via PCR with 
primers CJ1 and CJ2, as described previously53. Cascade EMSAs were performed by incubating 
0.3 nM of the PCR product with increasing Cascade concentrations (0.13, 0.22, 0.37, 0.62, 1.0, 
1.7, 2.9, 4.8, 8 nM for WT and Cascade(3R); 1.8, 4.6, 12, 29, 72, 180, 450  nM for Cascade(5A) ) 
for 30 minutes at 62°C in Binding Buffer (20 mM HEPES [pH 7.5], 150 mM NaCl, 2 mM MgCl2, 1 
mM DTT, 0.2 mg ml-1 BSA, 0.01% Tween-20). The reactions were resolved on a 5% native PAGE 
gel with 0.5X TBE Buffer (45 mM Tris-HCl [pH 8.0], 45 mM boric acid, 1 mM EDTA). Gels were 
visualized using a Typhoon scanner (GE) and quantified in ImageQuant TL v8.1 (GE). The 
fraction of bound DNA was fit to the hyperbolic curve to obtain Kd values. All experiments were 
repeated in triplicate. 
DNA substrates for single-molecule microscopy 
DNA substrates with mutated target sequences were generated by cloning the mutated targets 
into helper plasmids pIF152 and pIF153 that had ~200 bp of flanking homology with λ-phage 
DNA65. PCR products containing the large homology arms were recombineered into E. coli 
lysogens and the recombinant DNA purified from packaged phage particles65.  To functionalize 
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the DNA ends for single-molecule experiments, we combine 125 μg of purified λ-phage DNA 
with 2 μM of biotinylated oligos (IF001or IF003 or (Table 1)). For double-tethered DNA curtains, 
a second dig-labeled oligo was annealed to the second DNA end (oligos IF002 or IF004). After 
ligation, the reaction was separated over a Sephacryl S-1000 column (GE, #45-000-084) to 
purify full length labeled DNA. The DNA was stored at 4°C.  
Single-molecule fluorescence microscopy and data analysis 
All single-molecule imaging was performed using a Nikon Ti-E microscope in a prism-TIRF 
configuration equipped with a motorized stage (Prior ProScan II H117) containing microfluidic 
flowells housed in a custom stage adapter. The flowcell was illuminated with 488 nm 
(Coherent), 532 nm (Ultralasers), and 633 nm (Ultralasers) lasers through a quartz prism (Tower 
Optical Co.)40. A 60x air objective and a custom built microscope stage heater were used to 
maintain the flowcell near the optimal TfuCascade temperature. 
To prepare double-tethered DNA curtains for single-molecule imaging, 40 µL of liposome stock 
solution (97.7% DOPC, 2.0% DOPE-mPEG2k, and 0.3% DOPE-biotin; Avanti #850375P, 
#880130P, #870273P, respectively) was diluted into 960 µL Lipids Buffer (10 mM Tris-HCl [pH 
7.8], 100 mM NaCl) and incubated in the flowcell for 30 minutes. Next, 50 ng µL-1 of goat anti-
rabbit polyclonal antibody (ICL Labs, #GGHL-15A) diluted in Lipids Buffer was injected into the 
flowcell and incubated for 10 minutes. The flowcell was washed in Imaging Buffer (40 mM Tris–
HCl [pH 7.8], 2 mM MgCl2, 0.2 mg mL− 1 BSA) followed by 10 minute incubation with 5 ng µL-1 of 
digoxigenin monoclonal antibody (Life Technologies, #700772) diluted in Imaging Buffer. Next, 
0.1 mg mL-1 Streptavidin diluted in Imaging Buffer was injected into the flowcell and incubated 
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for 10 minutes. Lastly, 12.5 ng µL-1 of the biotin- and dig-labeled DNA substrate was injected 
into the flowcell. Single-tethered curtains were prepared by omitting the anti-rabbit antibody 
and digoxigenin antibody steps. In all experiments, Imaging Buffer was supplemented with 50 
mM NaCl. In experiments using Sortase labeled Cas3 and/or Cas1-Cas2, 10 mL Imaging Buffer 
was supplemented with 1 mM Trolox (Sigma-Aldrich, #238813-5G), 500 units of catalase 
(Sigma-Aldrich), 70 units of glucose oxidase (Sigma-Aldrich), and 1% glucose (w/v). 
To observe Cascade diffusion and target search, 150 μL of 0.1 nM QD-labeled Cascade in 
Imaging Buffer supplemented with 50-150 mM NaCl was injected into a flowcell with pre-
assembled double-tethered DNA curtains. Excess Cascade was removed and DNA-bound 
Cascade complexes were imaged at a 200 ms framerate for 10 minutes. In experiments where 
Cascade was pre-bound to the DNA target, 10 nM Cascade was incubated with 1.3 μg of 
biotinylated and digoxigenin labeled DNA at 55 °C for 10 minutes, followed by a 10-minute 
incubation at room temperature. The DNA bound Cascade was then diluted to 1 mL in Imaging 
Buffer with 50 mM NaCl and injected into flowcells prepared for single or double-tethered DNA 
curtains. Cascade was then labeled in situ by injecting 150 µL of 10 nM anti-FLAG antibody 
conjugated QDs.  
Cas3 translocation was observed by injecting 10 nM Cas3 diluted in 150 μL Imaging Buffer onto 
single-tethered DNA curtains with Cascade pre-bound to its target DNA. Experiments using 
ATTO647N-Cas3 used a five second frame rate and a computer-controlled digital shutter 
(Vincent Associates) on the 633 nm laser to limit Cas3 photobleaching. In these experiments, 
Cascade was visualized using a spectrally distinct 605 nm QD. Wild type (unlabeled) Cas3 was 
used in experiments with fluorescent Cse1 or fluorescent Cas1-Cas2 complex.  
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To observe Cas3-roadblock collisions, Cascade was pre-bound to the DNA target at 55°C. Then 5 
nM of 3xHA-EcoRI(E111Q) or 2.5 nM 3xHA-LacI were incubated with the Cascade-DNA 
substrate on ice for 5 minutes, followed by dilution into 1 mL of Imaging Buffer. The protein 
bound DNA was then injected into flowcells prepared for single-tethered DNA curtains. All 
proteins were labeled in situ. HA labeled proteins were labeled by injecting 150 μL of 1 nM of 
anti-rabbit conjugated Qdots (Thermo Q-11461MP) pre-bound to 0.2 nM anti-HA antibody (ICL 
Labs, RHGT-45A-Z) diluted in Imaging Buffer. For experiments involving RNAP complexes, 
Cascade was pre-bound to the DNA at 55°C. E. coli RNAP holoenzyme was fluorescently labeled 
with a streptavidin-coated QD (Finkelstein et al., 2010) and injected into the flowcell in the 
presence of 25 μM of GTP, 1 mM ATP, and 25 μM UTP. The ATP concentration was higher to 
support Cas3 translocation. RNAP that was not engaged to the promoter was removed from the 
DNA by a 700 μL heparin wash (0.2 mg mL-1). Cascade was fluorescently labeled by a QD in situ. 
Then, 10 nM unlabeled Cas3 was injected and collisions between the RNAP and Cascade/Cas3 
complexes were visualized by recording ∼10-min movies at 5 frames per second.  
For force-dependent experiments, 12 μg of biotinylated and digoxigenin labeled λ-DNA 
molecules were conjugated to 4 mg of 1 μm superparamagnetic beads (NEB, #S1420S) in Lipids 
Buffer overnight at room temperature. DNA-conjugated beads were washed 3 times and 
resuspended in 75 μL of Lipids Buffer. Cascade (30 nM) was pre-bound to 15 μL of DNA 
conjugated beads at 55°C and cooled to room temperature. DNA was captured in flowcells 
assembled with liposomes lacking biotinylated lipids and streptavidin. Cascade-bound DNA was 
injected into the flowcell, and concentrated at the surface with a rare earth magnet for 10 
minutes. The DNA bound to digoxigenin antibodies at the chromium barriers. Excess DNA and 
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beads were flushed out of the flowcell. To initiate Cas3 translocation, 10 nM of Cas3 was 
injected into this flowcell at 50 µL min-1. The flow rate was subsequently increased to the 
desired applied force. To calculate the force-dependent elongation of DNA conjugated beads, 
single particle tracking was used to measure the mean extension of bead-tethered DNA 
molecules from the chromium barriers at flow rates ranging from 100 to 1200 μL min-1.  
To image fluorescent Cas1-Cas2, Cascade was pre-bound to the target and labeled via the 
3xFLAG epitope on Cas6, as described above. Fluorescent Cas1-Cas2 was diluted to a final 
concentration of 1 nM in Imaging Buffer containing 150 mM NaCl, and injected onto single-
tethered DNA curtains. Free Cas1-Cas2 was washed out of the flowcell, followed by injection of 
10 nM Cas3 when indicated. 
Co-immunoprecipitation and Western Blotting 
Purified Cas1-Cas2 (225 nM) was incubated with purified Cascade (225 nM) on ice for 30 
minutes in Western Buffer (40mM Tris-HCl [pH 8.0], 0.2 mg/mL BSA, 150 mM NaCl, 10% 
glycerol, 2 mM MgCl2, and 2 units/mL DNase I. To pull-down by TwinStrep-Cas2, the sample was 
applied to Strep-tactin Superflow 50% suspension beads (catalog# 2-1206-002, IBA). Anti-FLAG 
M2 Magnetic Beads (catalog# M8823-1ML, Sigma) were used to carry out the reciprocal 
experiment by pulling-down via Cascade-1xFLAG. The beads were then washed three times 
with Western Buffer, and the samples removed by adding 3x-FLAG peptide or boiling the beads. 
Supernatant was resolved on a 15% SDS-PAGE gels and probed by standard Western blotting.  
Data Analysis  
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Fluorescent particles were tracking using an in-house ImageJ script (available upon request). 
Trajectories were used to calculate the mean-squared displacement and the diffusion 
coefficients for Cascade, or the velocity and processivity for the Cas3-containing complexes, as 
described previously 66,59. Binding lifetimes were fit to either a single exponential decay or a 
biexpoential decay using a custom MATLAB script (Mathworks R2015b). The biexpoential fits 
were tested to be appropriate using an f-test applied to the survival curve data59.  For pause 
analysis, a molecule was considered paused if it stayed within a stationary window for four 
continuous frames (0.8 secounds). This window was defined as 3-fold the standard deviation 
(S.D.) of the fluctuations of a stationary Cascade at its target45. Pause location was recorded in 
relation to the pedestal located at the digoxigenin labeled end of the DNA.  
Translocating Cas3 was defined as Cas3 that left the target window for at least four continuous 
frames (> 800 ms). Looping Cas3-Cascade molecules were defined by scoring whether Cascade 
also left the target window with Cas3. In contrast, independently moving Cas3s were defined by 
scoring traces where Cascade remained stationary while Cas3 moved away from the target 
window.  
Roadblock collision analysis.  Collisons were defined when Cascade fluorescence co-localized 
with the roadblock (EcoRI or LacI). The roadblock was considered pushed if it moved away from 
its binding site for four adjacent frames (0.8 seconds).  
Cse1 homology modeling.  Multi-sequence alignment was performed with the ConSurf 
evolutionary conservation tool using the HMMR homolog search algorithm, and MAFFT 
multiple sequence alignment methods47. Conservation of positive residues was calculated as 
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the percentage of a total of 150 divergent Cse1 homolog sequences that had an Arginine, 
Lysine, and Histidine for each residue aligned against TfuCse1. 
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